











































































































































Cardiovascular disease (CVD) is a broad term for a range of diseases affecting the heart 
and blood vessels (capillaries and veins) (Anthea, 1993). 
Specifically it refers to any disease that affects the cardiovascular system, principally 
cardiac disease, vascular diseases of the brain and kidney, and peripheral arterial disease 
(Kelly, 2010). 
CVD is the leading causes of deaths worldwide, through since the 1970s, cardiovascular 
mortality rates have declined in many high-income countries (Institute of Medicine of the 
National Countries, 2010). At the same time, cardiovascular deaths and disease have 
increased at a fast rate in low- and middle-income countries (Mendis, et al., 2011). It is 
expected that by 2020, CVD would prevail as the leading cause of death and disability 
over infectious diseases globally (Murray, et al., 1997). Although very important progress 
in the treatment and prevention of these diseases has been made, intense contemporary 
research efforts are aiming to unravel new diagnostic tools (Campos, et al., 2013). 
The cardiovascular system is regulated by the autonomic nervous system, the renin-
angiotensin-aldosterone system, nitric oxide (NO) and other factors including 
neuropeptides (Wong, et al., 2012). 
Over past three decades, the field of medicine has made a drastic progress in diagnosis, 
prevention and treatment of CVD. The Framingham Heart Study and the Seven 
Countries’ Study were the two major studies that made significant contribution in 
identifying major risk factors for CVD (Murray, et al., 1997) (Farouhi, et al., 2006). Substantial 
body of evidence, supporting the reduction of conventional risk factors, led to the search 
of new emerging risk factors. Over 300 conventional risk factors for CVDs have been 
discovered which mostly fall into two broad categories: a) modifiable and b) non-
modifiable. Modifiable risk factors (i.e. high blood pressure, high blood cholesterol, 
tobacco use, diabetes mellitus and obesity) (Kelly, 2010) are the factors that if treated and 
controlled would reduce the CVD risk, while non-modifiable risk factors (i.e. genetic 
factors) could not be modified to reduce the CVD burden (Smith, et al., 2000) (Expert panel 





underutilized and possessed lower accuracy than desired (Brotman, et al., 2005), from this 
observation derived the necessity to explore new risk factors for CVD. 
Emerging risk factors are broadly categorized as either early markers risk or markers of 
existing disease (Assman, et al., 2005) (Helfand, et al., 2009). 
Among early markers there are genetic polymorphisms identified in genes encoding 
HDL, LDL, triglycerides CRP and body mass index which lead to an increased risk of 
MI (Thanassoulis DG, 2010). 
On the other hand there are C-reactive protein levels, carotid intima-media thickness, 
lipoprotein (a) levels, apolipoprotein B levels, homocysteine levels, oxidative mediators 
(such as myeloperoxidase and F2-isoprostane) and vitamin D levels among markers of 
existing disease (Gupta, et al., 2013). 
Recently, several large, prospective, longitudinal studies have revealed that the relation 
between depression and CVD is significant and independent of conventional risk factors 
(Jiang, et al., 2002). Indeed, a large body of evidence has emerged to suggest that 
depressive disorder is a risk factor for heart diseases, both etiologically and 
prognostically. Actually, depression is associated with changes in an individual’s health 
status that may influence the development and course of cardiovascular disease, 
including noncompliance with medical recommendations, as well as the presence of 
cardiovascular risk factors such as smoking and hypertension. In addition, depression is 
associated with physiologic and pathologic changes, including nervous system 
activations, cardiac rhytm disturbances, multidistrectual inflammation and 
hypercoagulability that negatively influence the cardiovascular system. Furthermore, 
stress may be an underlying trigger that leads to the development of both depression and 
cardiovascular disease (Joynt, et al., 2003). 
Beyond the fact that the risk factors that lead to CVDs are different, CVDs result the 
major clinical consequence of thrombotic events, in particular of arterial thrombosis, 
venous thromboembolism (VTE), and disseminated intravascular coagulation (DIC). 
 
Arterial thrombosis is the most common cause of death in the developed world. The 
primary cause of arterial thrombosis is either instability or rupture of an atherosclerotic 
plaque resulting in localized clot formation and blockage of blood flow with subsequent 





to as white clots. Various risk factors can increase the incidence of arterial thrombosis, 
such as smoking, hypertension, hyperlipidemia and diabetes mellitus (Owens, et al., 2010). 
Venous thromboembolism (VTE), which is a collective term for both deep-vein 
thrombosis (DVT) and pulmonary embolism (PE), is the third leading cause of 
cardiovascular death in the developed world. Commonly formed in the large veins of 
the leg, these clots are primarily composed of red cells and fibrin. As opposed to arterial 
thrombosis, which occurs due to arterial injury and exposure of the sub-endothelium, 
venous thrombosis mainly occurs due to changes in the composition of the blood, 
changes in blood flow and/or activation of the endothelium (Mackman, 2008) (Eppihimer, et 
al., 2000). Many different factors can increase the incidence of VTE, such as the presence 
of cancer, obesity and major surgery (Cushman, 2007) (Urbach, et al., 2003). Thrombophilia is 
the propensity to develop thrombosis as a result of changes in the blood itself. 
Disseminated intravascular coagulation (DIC) is characterized by microvascular 
thrombosis (Levi, et al., 1999). Sepsis and endotoxaemia are the most common pathologic 
conditions leading to DIC (Levi, et al., 1999) (Baglin, 1996). DIC can also be caused by 
severe trauma, such as surgery, resulting in the release of “tissue debris” into the 
circulation and subsequent activation of coagulation (Levi, 2005) (Levi, et al., 1997) (Gando, 
2001). 
Although several factors involved in these processes have been identified and targeted 
successfully with therapeutic interventions (Smith, et al., 2006) (Krumholz, et al., 2006), there 
are clearly many that remain to be elucidated. Because of the multifactorial nature of 
thrombosis and the difficulty in elucidating factors involved in human disease, there is a 
need for in vivo animal models to explore the pathophysiolgy of thrombosis. 
 
1.1 Key  regulators of  thrombosis - Thrombus formation within a vessel is the 
precipitating event in multiple vascular disease processes, including MI, thrombotic 
cerebrovascular events and venous thrombosis; however, the pathophysiological 
processes regulating these diseases are distinct. In venous thrombosis, primary 
hypercoagulable states, reflecting defects of the proteins of coagulation and fibrinolysis, 
or secondary hypercoagulable states, involving abnormalities of blood vessels and blood 
flow, lead to thrombosis (Andreotti, et al., 2005). In contrast, arterial thrombosis is highly 





Under normal circumstances, the hemostatic process is a delicate balance of 
prothrombotic and antithrombotic factors in the vasculature. Normal hemostasis 
prevents 1) uncontrolled hemorrhage, 2) keeps the blood in a fluid state and 3) removes 
blood clots after restoration of vascular integrity; however these same pathways 
regulating hemostasis lead to pathological thrombosis and vessel wall occlusion. 
Upon injury, complex processes are activated and involve interaction between the 
vascular wall, platelets, leukocytes, coagulation proteins, and other as yet unidentified 
components (Randal, et al., 2007). Specifically the first component that contributes to 
hemostasis is the coagulation system with the expression of tissue factor, while the 
second important component starts with platelet activation, which not only contributes 




Figure 1 Key regulators of thrombosis. Platelets, vessel wall and monocytes are all involved in 
thrombosis. 
 
1.1.1 Platelets and vessel wall in the thrombosis - From the first characterization 
of platelets in the 19th century as “small, curious beads or grains which accumulate to 
each other to irregular clusters”, the knowledge about platelets grew very fast. At 
present, it is widely established that platelets are not only implicated in thrombotic but 





metastasis (Weber, et al., 2004) (Lievens, et al., 2001) (Gawaz, et al., 2005). As a-nucleate cells 
with a diameter of 2-4 m, platelets are released from megakaryocytes in the bone 
marrow (Jurk, et al., 2005) and show a lack of genomic DNA (Italiano, et al., 2003) but still 
contain megakaryocyte-derived mRNA and translational machinery needed for protein 
synthesis (Nieswandt, et al., 2009). The established function of platelets is to stop 
hemorrhage after tissue trauma or vascular injury. On the other hand, platelets form 
thrombus at site of ruptured atherosclerotic plaques, and in this way trigger heart attack 
and stroke (Jurk, et al., 2005). The immobilization of platelets at sites of vascular injury 
requires specific platelet-vessel wall- (adhesion) and platelet-platelet- interaction 
(aggregation). The adhesion of platelets to the subendothelial matrix is the initial step in 
primary hemostasis. Platelets interact with extracellular matrix (ECM) proteins via 
specific adhesive glycoproteins (GP). In contrast to resting platelets, which are discoid 
with homogenously distributed granules, activated platelets show a change in the 
assembly of cytoskeleton proteins resulting in a shape change with extensive formation 
of pseudopodia originating from the plasma membrane (Fox, 1993). Further, the granules 
centralize and fuse with the plasma membrane via exocytosis with secretion of the 
granule content. Some secretion products, such as adenosine diphosphate (ADP) and 
serotonin, potentiate the stimulation of more platelets, which are attracted to the 
damaged vessel wall. The activation of platelets is associated with the binding of 
fibrinogen (Savage, et al., 1996) to its major receptor GPIIbIIIa, which is essential for 
platelet bridging and subsequent aggregation. Fibrinogen is thought to play an 
important role particularly at the low shear rates characteristic of the venous circulation. 
Anyway Ni et al. demonstrated, in fibrinogen- null mice, that platelet deposition and the 
onset of thrombus formation are the same as in WT mice (Ni, et al., 2000). However, 
thrombi in fibrinogen-null mice are unstable and embolize as they become larger, 
demonstrating that also other adhesion molecules are important for the formation of a 
stable clot. During secondary hemostasis, the amplification of platelet stimulation leads 
to procoagulant activity, thrombin generation and formation of a stable platelet-fibrin 
plague with subsequent clot retraction (Jurk, et al., 2005). In certain conditions of flow, 
platelets have to slow down to stop at sites of vascular damage. The high molecular 
weight (1-10 MDa) multimeric plasma protein von Willebrand factor (vWF) associates 





as a substrate of platelet adhesion predominantly under high shear. Different types of 
collagens are present in the vessel wall, of which collagens I and III are considered the 
most important in supporting platelet adhesion to the damaged vasculature. Type I, III 
and VI collagen filaments have affinity for vWF and the two molecules are associated in 
the ECM. While soluble vWF does not bind to platelets to prevent aggregation in the 
normal circulation, immobilized vWF onto collagen is highly reactive toward flowing 
platelets. This may be because immobilized vWF assumes an extended shape under the 
effect of shear allowing its A1 domain to interact with platelets (Siedlecki, et al., 1996) 
(Schneider, et al., 2007). Platelet adhesion to vWF is a dynamic process in which initial 
platelet tethering is characterized by transient interactions mediated through GP 
IbThis deceleration then allows platelets to form new bonds with slower intrinsic 
binding kinetics and to become activated (Savage, et al., 1998). It has long been known that 
the GP Ib/IX/V complex is the major platelet receptor mediating interaction with vWF. 
In addition to vWF, the GP Ib/IX/V complex also binds to other adhesive proteins 
(collagen, thrombospondin-1), -thrombin and coagulation factors. In vivo experiments 
on vWF-null mice display prolonged bleeding times and spontaneous bleeding in about 
10% of neonates (Denis, et al., 1998). Anyway, in the complete absence of vWF, platelet 
accumulation on the vessel wall is significantly decreased but not absent. These results 
argue both for the importance of vWF in platelet deposition on the vessel wall and for 
vWF-independent mechanism for arterial thrombus formation. On the other hand mice 
expressing modified GP Ib can not form a thrombus, demonstrating that this 
glycoprotein is essential for arterial thrombus formation (Bergmeier, et al., 2006). 
GPVI, the major signaling collagen receptor on platelets, is a member of the 
immunoglobulin superfamily (Clemetson, et al., 1999). Deficiency in GPVI leads to 
impaired collagen-induced platelet adhesion and aggregation and is associated with a 
mild bleeding disorder (Moroi M, 1989). 
However, the central platelet receptor in regulating platelets aggregation is the IIb3 
(GPIIb/IIIa) that link activated platelets through fibrinogen bridges. Interaction between 
GPIIb/IIIa and its ligand is associated with molecular conformational changes, resulting 
in a firm connection. GPIIb/IIIa can bind also other ligands such as vWF, fibronectin, 





Integrin 21 (GPIa/IIa) is a less abundant platelet integrin (Clemetson, et al., 2007). Also it 
binds to collagen. As platelets on immobilized GPIa/IIa show limited signaling, it 
appears that this integrin mainly serves to support platelet interaction via the other 
collagen receptors (Munnix, et al., 2008). Integrin v3 (binding vitronectin and 
fibrinogen), integrin 51 (binding fibronectin) and integrin 61 (binding laminin) are 
moderately expressed on platelets (Clemetson, et al., 2007) and also their relevance is 
moderate (Gruner, et al., 2003). The adhesive molecule fibronectin, an ~500 kDa 
glycoprotein dimer, is abundantly present in blood plasma, megakaryocytes, and -
granules of platelets (Maurer, et al., 2010). Data from men or mice lacking fibronectin 
suggest that it has only a limited role in normal hemostasis. However, fibronectin levels 
do affect thrombus formation and thrombus stability (Maurer, et al., 2010) (Ni, et al., 2003). 
Vitronectin also is abundantly present in plasma and ECM, coordinates migration and 
signaling of blood cells and vascular cells, but its role in platelet activation is unclear 
(Preissner, et al., 2011). Other vitronectin ligand is PAI-1. Vitronectin binding stabilizes 
PAI-1 as a fibrinolytic inhibitor, which renders fibrin clot less susceptible for lysis 
(Zhou, et al., 2003). Two other adhesive proteins with an established role in platelet-vessel 
wall interaction are thrombspondin-1 and laminin. Thrombospondin-1 is released from 
-granules of platelets and binds to CD36, resulting in platelet activation (Jurk, et al., 
2003). Laminin is a large glycoprotein (920 kDa) of the ECM and the basement 
membrane, synthetized by endothelial cells, which becomes exposed after mild vascular 
injury (Hawiger, 2001).  
Platelet activation by ECM proteins results in the release or production of several 
granule components that modulate functions of interacting platelets and blood and 
vascular cells. Several secretion products of immobilized platelets stimulate additional 
circulating platelets, which are recruited to form aggregates. The dense bodies of 
platelets contain important secondary agonists like ADP or serotonin. ADP is predicted 
to be prominent amplifier of initial platelet activation (Gachet, 2001). There are two 
important ADP receptors on the platelet surface. The P2Y1-receptor mediates 
mobilization of Ca2+ and shape change and transient aggregation (Fabre, et al., 1999). The 
P2Y12- receptor is believed to potentiate platelet secretion and to be involved in 
sustained irreversible aggregation (Dorsam, et al., 2004). Serotonin amplifies together with 





augmenting the retention of procoagulant proteins like fibrinogen and thrombospondin 
on the platelet surface (Dale, et al., 2002). The -granules contain large adhesive proteins 
(vWF, thrombospondin-1, vitronectin, fibronectin), mitogenic factors (PDGF, VEGF, 
TGF), coagulation factors and protease inhibitors (protein C, PAI-1, TFPI) that are 
released immediately after platelet activation. Other soluble agonists of platelets are 
thromboxane A2 (TXA2) produced by the platelet cyclooxygenase/thromboxane 
synthase complex and thrombin formed at the platelet surface. 
Indeed the formation of a stable platelet plug during secondary hemostasis is 
characterized by thrombin-mediated conversion of fibrinogen to fibrin. Thrombin is also 
generated on surfaces of blood and vascular cells. However, the platelet membrane 
contains a specific lipid assembly and receptors with high-affinity binding sites for 
clotting factors, a favored preferential and specialized locus to induce and modulate 
secondary hemostatic processes (Monroe, et al., 2002). 
Finally, platelets carry a multitude of inflammatory mediators, such as chemokines, 
including the most abundant platelet chemokine, PF4 (CXCL4), which can deposit onto 
the vessel wall and contribute to the development of vascular lesions (Pitsilos, et al., 2003). 
Further, platelets shed proinflammatory microparticles during storage and upon 
activation, which have the potential to affect the function of the vessel wall and 
circulating leukocytes (Agouni, et al., 2008). 
 
1.1.2  Coagulation  system - In the 1960s, two independent groups constructed a 
model for coagulation that resembled a waterfall or cascade. Therefore, this model was 
aptly named the coagulation cascade model (Davie, et al., 1964) (Macfarlane, 1964). Herein, each 
clotting factor consists of a pro-enzyme that is converted to an active enzyme by the 
upstream activated clotting factor. It was also suggested that two different cascades 
exist and converge in FX activation. These are named the intrinsic pathway, so called 
because all the components are present in the blood, and the extrinsic pathway 
requiring an external factor (Tissue Factor (TF) from the extravascular tissue. 
 
The coagulation factors are usually divided into two biochemical classes: the serine 
protease (i.e., (pro)thrombin, FVII, FIX, FX and FXI) and serine protease cofactors (i.e., 





to the group of serine proteases. These proteolytic enzymes are the active components 
of the clotting machinery and share structural features. Full-length FVII, FIX, FX and 
protein C consist of an NH2-terminal -carboxylated glutamic acid domain, two 
epidermal growth factor-like domains (EGF1 and EGF2) and a serine protease domain. 
Prothrombin has a similar structure but contains two kringle domains instead of the 
EGF domains, while FXI is a homodimer with four apple domains in each subunit. 
Upon vasculature disruption sub-endothelial cell like smooth muscle cells and 
fibroblasts become exposed to the bloodstream and expose a key initiator of the 
coagulation cascade, TF, which, acting as a cofactor, binds coagulation FVII and 
converts FIX and FX into FIXa and FXa, respectively. This allows FXa to associate 
with cofactor FVa to form a prothrombinase complex on TF-expressing cells. The 
amplification of the coagulation cascade promotes the conversion of prothrombin (FII) 
into thrombin (Monroe, et al., 2006). The slowly accumulating amounts of thrombin will 
further activate platelets that have adhered to a site of injury. In parallel, thrombin will 
convert (platelet-derived) FV into FVa, thus amplifying prothrombinase activity, and 
will convert FVIII into FVIIIa, which acts as a cofactor to FIXa on the surface of 
activated platelets to support FXa generation. In addition, thrombin converts FXI into 
FXIa. Activated FXI converts FIX into FIXa, which then associates with thrombin-
cleaved FVIII. On phosphatidylserine-exposing cell membranes, the tenase complex of 
FIXa/FVIIIa catalyzes the conversion of FX to FXa, after which the FXa/FVa complex 
produces sufficient amounts of thrombin to massively form fibrin fibers. As a final step, 
the thrombin-activated plasma transglutaminase FXIIIa catalyzes the formation of 
covalent crosslink between adjacent fibrin chains to yield an elastic, polymerized fibrin 







Figure 2 Coagulation cascade. The coagulation cascade comprises two different pathway: these are 
named the intrinsic pathway, so called because all the components are present in the blood, and the 
extrinsic pathway requiring an external factor (Tissue Factor (TF) from the extravascular tissue. 
 
On the other hand, several studies have clearly shown that extensive negative control of 
coagulation (Broze, et al., 1988) (Jesty, 1978) is essential to prevent uncontrolled, 
widespread clot formation. First, circulating protease inhibitors, such as antithrombin, 
considered one of the most important inhibitors of thrombin generation and function 
and acts inhibiting FIXa, FXa and thrombin, heparin cofactor II, and TFPI that inhibits 
coagulation by direct inhibition of free FXa and by interaction with the transient 
TF/FVIIa/FXa complex (Girard, et al., 1989). The second anticoagulant modality is 
provided by the enzyme-based protein C/protein S pathway that establishes proteolytic 
inactivation of FVIIIa and FVa, thus suppressing tenase and prothrombinase actions. 
 
Tissue Factor (TF) and thrombosis. Tissue Factor (TF), formerly known as 
thromboplastin or CD142, is a 47-kDa transmembrane glycoprotein expressed in 
extravascular tissue, by fibroblasts and smooth muscle cells, serving as a hemostatic 
“envelope”, poised to activated coagulation upon vascular injury (Versteeg, et al., 2013) 
(Wilcox, et al., 1989). The TF gene is located on chromosome 1 and consists of 6 exons 





form have been described (Bogdanov, et al., 2003). The mature TF protein comprises a 219- 
amino acid extracellular region, a hydrophobic transmembrane region, a short 
intracellular tail of 21 amino acids. The external part consists of two fibronectin-type III 
domains, each with an extracellular disulfide bond (Versteeg, et al., 2013). Generally, active 
TF is not exposed to the blood stream, but endothelial cells and adhered leukocytes may 
express active TF as a response to injury or to inflammatory stimuli such as endotoxin, 
chemokines or cytokines (Erlich, et al., 1999) (Warr, et al., 1990). For example endothelial TF 
is induced by cytokines such as tumor necrosis factor- (TNF-), interleukin-1 or 
CD40 ligand (Bavendiek, et al., 2002); by biogenic amines such as serotonin (Kawano, et al., 
2001) or histamine (Steffel, et al., 2005), and by mediators such as thrombin, oxidized LDL 
or vascular endothelial growth factor (Camera, et al., 1999). In addition to its role in 
coagulation, TF participates in other cellular processes. It is involved in migration and 
proliferation of vascular smooth muscle cells (Pyo, et al., 2004) and it has also been 
observed to promote tumor neovascularization and metastasis (Steffel, et al., 2006). 
Aberrant expression, initiates life-threatening thrombosis in a variety of diseases, 
including atherosclerosis, cancer and sepsis (Tremoli, et al., 1999) (Rickles, et al., 2003) (Rao, 
1992). For instance, rupture of atherosclerotic plaques exposes plasma clotting factors to 
high levels of TF with subsequent thrombosis (Tremoli, et al., 1999). TF is also expressed 
by circulating monocytes and tumor cells that may initiate disseminated intravascular 
coagulation (Rickles, et al., 2003) (Levi, et al., 1999). Finally TF may be shed from cells into 
the circulation in the form of microparticles (Giesen, et al., 1999) (Marmur, et al., 1993). 
Microparticles are 50- to 1000-nm membranes vesicles that are released from various 
cells. (Freyssinet, et al., 2010). This circulating TF has been referred to as blood-born TF 
and may contribute to thrombosis in different diseases but it is still unclear the strength 
of its influence. 
The level of circulating TF to thrombosis is currently a highly debated topic. Levels of 
TF in the vessel wall are reported to far exceed the amount in blood with an estimated 
ratio of 1000:1 (Butenas, et al., 2005) (Day, et al., 2005). Other investigators have reported 
higher concentrations of TF in the blood of healthy individuals (Diamant, et al., 2002) 
(Giesen, et al., 1999) (Siddiqui, et al., 2002). 
Transgenic mice mTF-/-/hTF+, generated from TF deficient embryos with a minigene 





different tissues, have a prolonged tail bleeding time and are prone to excessive 
bleeding during major surgery compared to wild-type mice. In addition, whole blood 
clotting time is significantly prolonged using blood from low TF mice compared with 
wild-type mice (Pawlinski, et al., 2004), suggesting that low TF mice have reduced TF in 
both the vessel wall and the blood. Low TF mice have prolonged occlusion times 
compared to wild-type mice in a carotid model of thrombosis involving oxidative 
damage to the vessel wall. Similarly, in a heat-induced injury model of thrombosis 
using the microvasculature of the cremaster muscle, low TF mice have reduced TF and 
fibrin levels in the thrombus compared with wild-type mice (Pawlinski, et al., 2004). Bone 
marrow transplantation experiments showed that the occlusion time in the carotid 
thrombosis model was not affected by dramatically reducing TF in hematopoietic cells 
(Pawlinski, et al., 2004), providing evidence that cells within the vessel walls were the 
primary source of TF-initiated clotting in this model. In contrast, reducing 
hematopoietic cell TF was associated with a significant reduction in TF and fibrin levels 
in the model of microvascular thrombosis, suggesting that hematopoietic cells release 
TF positive microparticles into the circulation and that these microparticles contribute to 
thrombosis. Indeed, Furie and colleagues have shown that microparticles bind to 
activated platelets within the thrombus via an interaction between PSGL-1 and P-
selectin (Falati, et al., 2003). 
Platelets appear to acquire TF through interaction TF-bearing microparticles from 
monocytes (Del Conde, et al., 2005) (Falati, et al., 2003) (Hrachovinova, et al., 2003), but platelets 
also contain TF pre-mRNA (Camera, et al., 2003), which can be spliced into mature mRNA 
upon platelet activation, culminating in limited TF protein expression and procoagulant 
activity (Schwertz, et al., 2006). Because platelets secrete large quantities of the TF 
antagonist tissue factor pathway inhibitor (TFPI), the physiological relevance of this 
low expression of TF to hemostasis is unclear. 
Recently Camera’s group demonstrated that in acute coronary syndrome (ACS) patients 
more than 3 times as many circulating platelets expressing TF on their surface as are 
found in stable angina (SA) patients and in controls. They observed that not only is the 
number of TF-positive platelets higher in ACS, but each platelet express twice the 
number of TF molecules than in the other two groups, so that the total capacity to 





platelet-leukocyte aggregates (PLA) might be responsible not only for the increase in 
thrombus formation triggered by unstable plaque rapture, but also may provide potential 
distal sites for the generation of new thrombi (Brambilla, et al., 2008). Even if Camera and 
colleagues have not performed a direct comparison of TF activity between platelets and 
monocytes, and even if the TF activity of a single monocyte is higher than that of a 
single platelet, the number of the latter in a thrombus is largely greater compared to the 
number of monocytes. Moreover, also TF mRNA is increased in ACS patients. 
Irrespective of the mechanism involved in platelet-produced TF (derived by their 
progenitors megakaryocytes or by a greater state of inflammation), the higher amount of 
TF mRNA found in platelets from ACS patients further strengthen their prothrombotic 
potential, especially in view of the platelet biosynthetic potential. The platelet-derived 
TF may contribute to fibrin formation and to the propagation and stabilization of a 
thrombus but can also participate, as recently shown, in several cellular processes that 
stimulate atherogenesis (Servoss, et al., 2002). 
 
1.1.3  Leukocytes  and  thrombotic  disorders – The involvement of leukocytes in 
thrombus formation, first observed in vivo by Giulio Bizzozero in 1881 (de Gaetano, 2011), 
was documented in in vitro experimental studies and in animal models (Wagner, 2005) 
(Cerletti, et al., 2010) (Cerletti, et al., 1999); however, the mechanisms of leukocytes 
involvement in thrombosis and their modulation are not completely clear. Most likely, 
leukocytes, besides a direct inflammatory effect, may interact with platelets, form mixed 
aggregates and participate in a final common thrombogenic effect (Cerletti, et al., 2012). 
The adhesion of leukocytes to platelets, deposited at the site of vascular injury, may 
represent an important mechanism by which leukocytes contribute to hemostasis and 
thrombosis (Harding, et al., 2007). 
Through transient and stable interaction with the endothelium, platelets may induce and 
propagate a chronic inflammation of the vessel wall, resulting in the development and 
progression of atherosclerotic lesions (Gawaz, et al., 2005). Under these inflammatory 
conditions, platelets show robust interaction with leukocytes (Van Gils, et al., 2009). This 
binding may occur in circulation or upon the adherence of platelets to the vascular wall, 
thereby providing an adherent surface to recruit leukocytes (Gawaz, et al., 2005) (Weber, et 





(Evangelista, et al., 1999) (Yang, et al., 1999) and this adhesion is subsequently stabilized through 
binding of Mac-1 to the GPIb (Simon, et al., 2000). Engagement of PSGL-1 and Mac-1 
induces an inflammatory cascade in monocytes, causing them to secrete effector 
molecules such as CCL5 (Weyrich, et al., 1996) (Neumann, et al., 1997). Lymphocytes have 
also been shown to interact with platelets, in a P-selectin-, CD154- and IIb3-dependent 
manner (Hu, et al., 2010). Also thrombospondin is reported to be involved in the cross-link 
between platelets and monocytes in early vascular injury via an interaction with GP IV 
on the surface of both cells (Silverstein, et al., 1989). The binding of platelets to leukocytes 
facilitates the interaction of the resulting platelet-leukocytes complexes to endothelial 
cells (Kirton, et al., 2000) (Kuckleburg, et al., 2011), providing a possible mechanism for the 
accelerated progression of atherosclerosis observed in mice challenged with activated 
platelets (Huo, et al., 2003) (Lievens, et al., 2010). Also, in patients with cardiovascular 
disease, platelet neutrophil and platelet monocyte complexes were shown to be elevated 
and presented a marker for acute MI (Ott, et al., 1996) (Furman, et al., 2001). Thus, platelet-
leukocyte aggregation might not only be a byproduct of local platelet activation at the 
site of an unstable or ruptured plaque but might also play an integral role in the 
pathogenesis of atherosclerosis and MI. 
However, the main physiological role of monocytes is attributed to innate immunity and 
the development of tissue macrophages and dendritic cells, but pathophysiological role 
of these, goes far behind these limits. Firstly, monocytes appear to be the major source 
of blood TF. Monocytes expose considerable quantities of TF on their surface being 
stimulated by a variety of inducers of which lipopolysaccharides (LPS) and C-reactive 
protein are especially important (Cermak, et al., 1993) (van der Logt, et al., 1994). The amount 
of TF mRNA performed by resting monocytes does not significantly affect the surface 
density of this protein but nonetheless, this appears to be responsible for the substantial 
variation of surface TF expression following stimulation by LPS (Sovershaev, et al., 2007). 
Monocytes transmigration through the arterial wall to tissues prior differentiation into 
macrophages is also associated with enhanced TF generation (McGilvray, et al., 2002). 
Moreover, monocytes stimulate TF expression by endothelial cells. Additionally, given 
that megakaryocytes do not express TF but the factor is present on platelets in 





involved in transfer of TF to platelets in addition to the production of the factor from 
stored intra-platelet mRNA (Panes, et al., 2007) (Scholz, et al., 2002). 
Multiple factors seen in coronary artery disease (CAD) promote excessive monocyte TF 
formation, that observation accords with the prothrombotic state typical for the disease. 
Indeed, extracts of human atherosclerotic plaque significantly enhance monocyte TF 
expression (Lambert, et al., 2007) (Muhlfelder, et al., 1999). 
Participation of monocytes in the prothrombotic conditions is not restricted to the 
expression of TF and generation of monocytes-platelet aggregates (MPA). The evidence 
support the impact of monocytes for thrombus generation, both directly via the secretion 
of procoagulant factors and indirectly, by promoting inflammation processes (Shantsila, et 
al., 2009). It is well known that inflammation affects the activity of various coagulation 
pathways. The inflammatory state also activates monocytes, which possess receptors for 
CRP and express CD40, a receptor for CD40 ligand (Bharadwaj, et al., 1999) (Crowell, et al., 
1991) (Stumpf, et al., 2003). CRP and CD40 ligand induce TF expression in human 
monocytes, thus linking inflammation, coagulation and thrombosis (Penn, et al., 2001) 
(Pepys, et al., 2001). Stimulation of human monocytes/macrophages through CD40 further 
induces the expression of interstitial collagenase (MMP-1), stromelysin (MMP-3), 
recognized elements of plaque destabilization and predictors of atherothrombotic events 
(Mach, et al., 1997). Activated monocytes are able to bind and activate coagulation factor 
X responsible for the conversion of prothrombin to thrombin. Additionally, monocytes 
can bind coagulation factor V and also produces its activated form on their surface 
(Kappelmayer, et al., 1993). Finally, to counterbalance their prothrombotic activity, resting 
monocytes produce thrombomodulin (Satta, et al., 1997), that is an essential cofactor of 
thrombin in the triggering of the natural anticoagulant protein C pathway, as explained 
previously. 
 
1.1.4 Fibrinolytic process in thrombosis regulation – Beside negative modulator of 
coagulation activation, the fibrinolytic system is another way to control hemostasis and 
subsequently to prevent thrombosis. Thrombolytic agents are plasminogen activators 
that convert the zymogen plasminogen to the active enzyme plasmin, which degrades 
fibrin and activates matrix metalloproteinases (MMPs) that, in turn, degrade 





plasminogen activators (PAs) have been identified: tissue type PA (tPA) and urokinase-
type PA (uPA), which binds to a cellular u-PA receptor (u-PAR). Inhibition of the 
plasminogen/MMP system occurs at the level of the PA, by specific PA inhibitors 
(PAIs), at the level of plasmin, by 2-antiplasmin, or at the level of MMPs. The two 
most important PAIs are PAI-1 and PAI-2. A deficient fibrinolytic response may be 
caused by impaired release of t-PA from the vessel wall or by increased rate of 
neutralization (Lijnen, et al., 1989). The PAI-1 concentration in plasma is increased in 
several diseases, including venous thromboembolism, obesity, sepsis, and CAD. On the 
other hand, increased levels of tPA or deficiency of 2-antiplasmin or PAI-1 may cause 
a bleeding tendency (Collen, 1999). 
 
2  Relationship  between  CVD  and  emerging  risk  factors:  the 
depression 
Some reviews about the link among depression and CVD have concluded that 
epidemiologic evidence supports “the notion that mood disorders confer risk for 
coronary disease, but it is premature to describe it as a causative factor” (Barrick, 1999). 
Interestingly, as we learn more about the expression of emotions, it appears these 
perceptions may simply be the language representation of the somatic feelings (Ranga, et 
al., 2003). In fact, sadness is often portrayed as feeling of heaviness in the chest or as a 
“broken heart”. Formerly, premature conclusions about a causal relationship for 
depression leading to coronary disease, resulting in gaps in the literature on the nature 
and duration of depression, the biological mechanisms linking these two disorders, and 
the effect of antidepressants treatment on the risk for coronary disease were drawn 
(Appels, 1997). On the other hand, recently, some studies have demonstrated that patients 
with depression have an increased risk of developing cardiovascular disease and a 2- to 
4-folds risk of mortality after experiencing a cardiac event (Penninx, et al., 2011). Despite 
the evidence that heart disease and depression are epidemiologically linked, this 
correlation is not well understood 
When considering the co-morbidity between major depressive disorders (MDD) and 
CVD it is important to differentiate between a) the prevalence and impact of MDD in 





Evidence in support of the relationship between depression and cardiovascular disease 
derives from growing array of cross-sectional surveys demonstrating the 
disproportionately elevated rates of depression among people with documented CVD 
compared with matched community-based samples. About a quarter of patients with 
angiographically demonstrated coronary atherosclerosis, recorded mild depressive 
symptoms and a further 11% had moderate to severe depression (Barefoot, et al., 1996). 
Importantly, the presence of depression in patients with CVD has been convincingly 
demonstrated to increase mortality (Frasure-Smith, et al., 1995) (Barefoot, et al., 1996) (Carney, et 
al., 1988). Frasure-Smith and Lesperance (Frasure-Smith, et al., 2008) recently extended this 
observation, documenting that depression and generalized anxiety disorder predict 
greater risk of major adverse cardiac events in the 2 years following MI. 
The association between mental and cardiovascular health was noted early in the 20th 
century when Malzberg (Malzberg, 1937) reported high mortality rates in hospital in 
patients with melancholia. It was not until 50 years later that evidence from prospective 
trials indicated that affective disorders participated in the development of CVD. This 
elevated risk is independent of classical risk factors such as smoking, obesity, 
hypercholesterolemia, diabetes mellitus and hypertension. In addition, in a recent meta-
analysis on the significance of depression in contributing to CVD development, 
emerges that depression at baseline is associated with the increased risk of development 
of a wide range of cardiovascular outcomes including MI, fatal and nonfatal heart 
disease and stroke (Van der Kooy, et al., 2007). 
In contrast, the frequency of developing depression after a cardiac event seems to be 
irrelevant. In fact, although 50% of patients immediately following MI are affected by 
mood disorders (Cassem, et al., 1977), the risk of developing depression is highest among 
patients who had prior episodes of depression (Lloyd, et al., 1983). Moreover, only 18% of 
50 patients with documented CAD show major depressive symptoms (Carney, et al., 1987). 
Thus, depressive symptoms are common, but full-blown major depression is seen only 
in 20% of patients (Ranga, et al., 2003). 
Therefore, it was formulated the hypothesis that depression is cause, not consequence, 
of cardiovascular events. 
Indeed, depression increases the risk of dying among patients who have just had an MI 





ischemia (Jiang, et al., 1997). Patients with established CAD and depressive symptoms 
showed more ischemia during mental stress testing (Jiang, et al., 1997), suggesting that 
even emotions within the normal range can play a key role in this relation. 
Patients with depression have been found to have elevated plasma norepinephrine, 
increased heart rates and reduced heart-rate variability. Reduced heart-rate variability 
has been associated with increased mortality in both CAD and chronic heart-failure 
(Jiang, et al., 1997) (Kleiger, et al., 1987), supporting this second hypothesis about the 
relationship between depression and cardiovascular disease. In addition, the depression 
reduces motivation and individuals do not care of their general health: depressed 
patients exercise less (Siegler, et al., 1997) (Adler, et al., 1994), eat poorly, smoke more and in 
general exhibit behaviors that increase the risk for cardiac disease. 
However, recently the existence of a common cause underlying both the depression and 
cardiovascular disease (Miller, et al., 2000) was hypothesized. In fact, the depression 
promotes a mild inflammatory response by fostering maladaptive health practices 
(cigarette smoking, sedentary lifestyle), triggering dysregulation of hormonal system 
(hypothalamic-pituitary-adrenocortical and sympathetic-adrenal-medullary axes) and 
increasing susceptibility to infections associated with atherosclerosis (Carney, et al., 2002). 
Over time this inflammatory response contributes to CVD progression by facilitating 
the growth of atherosclerotic plaque, precipitating the rupture of established plaque, and 
potentiating coagulation processes involved in thrombogenesis (Ross, 1999) (Libby, 2001). 
 
2.1 Potential mechanisms  linking cardiovascular disease and depression 
– While the mechanisms linking depression and cardiovascular disease are not well 
understood, a number of relationships have been identified which demonstrate the 
plausibility and coherence of a causal relationship. As the etiology of major depression, 
linked to brain monoaminergic neuronal dysfunction (Schildkraut, 1965) (Maas, 1975) 
(Linnoila, et al., 1982), alterations in monoamine receptor sensitivity (Charney, et al., 1981) 
and stress-induced activation of the hypothalamic-pituitary-adrenal (HPA) axis (Dinan, 
1994) with concomitant reduction in brain neurotrophins (Duman, et al., 1997). Several 
hypothesis were formulated. These include both direct biological mechanisms and 







2.1.1  Behavioral  mechanisms - A number of behavioral pathways appear to be 
involved in the relationship between psychological risk factors and CVD. Patients who 
are depressed have been found to be less likely to adopt a healthy lifestyle to reduce 
their risk of developing cardiovascular disease or to reduce the risk of disease 
progression once CVD is established (Carney, et al., 1987). Depressed patients have also 
been shown to be less likely to undertake physical activity (Paffenbarger, et al., 1994) and 
are less compliant with dietary restriction (Lesperance, et al., 1996). In addition, smoking 
rates are higher in depressed people and they also find it more difficult to quit (Anda, et 
al., 1990) (Glassman, et al., 1990). 
 
2.1.1.1  Adherence  to  treatment - A recent meta-analysis examining the impact of 
depression on treatment adherence, found that patients with depression were three times 
more likely to be non-adherent with treatment regimens (DiMatteo, et al., 2000). Cardiac 
patients with depression have also been shown to be less likely to follow 
recommendations to reduce ongoing cardiac risk factors following MI (Goldston, et al., 
2008). 
 
2.1.1.2  Social  support - A strong and consistent inverse relationship has been found 
between the magnitude of social support and both the development of CVD in initially 
healthy people and adverse prognostic outcome in those with existing CVD (Bunker, et 
al., 2003). Lack of both structural and functional social support has been implicated in the 
poorer prognosis in depressed cardiac patients. Factors such as living alone (Case, et al., 
1992), being socially isolated (Ruberman, et al., 1984), lack of available support (Gorkin, et al., 
1993), low perceived social support (Frasure-Smith, et al., 2000), lack of a close confidant 
(Williams, et al., 1992) and low emotional support (Berkman, et al., 1992) have all been found 




2.1.2.1  Dysregulation  of  the  hypothalamic‐pituitary‐adrenocortical  (HPA)  axis - 





pituitary-adrenal (HPA) axis (Dinan, 1994), resulting in over stimulation of the 
sympathetic nervous system, which in turn increases circulating catecholamines 
(adrenaline and noradrenaline) and serum cortisol (Banki, et al., 1992) (Brown, et al., 2004). 
Hypercorticolaemia causes blunted HPA activity and diminished feedback control 
(Carroll, et al., 1981). This neuro-hormonal abnormalities lead to an imbalance in 
sympathetic and parasympathetic activity, resulting in surges in heart rate and blood 
pressure and increasing the risk of atherosclerotic plaque rapture and acute coronary 
thrombosis. High levels of circulating cathecolamines also increase the irritability of the 
heart muscle, causing ventricular arrhythmias, which may lead to ventricular fibrillation 
and cardiac arrest (Carney, et al., 1999). Moreover the physiological consequences of 
increased circulating cortisol are diverse and include importantly, in the context of 
cardiac risk, the onset of metabolic changes, such as insulin resistance, 
hyperinsulinaemia, glucose intolerance and hyperlipaemia, and increased visceral fat 
mass (Posener, et al., 2000). 
 
2.1.2.2 Disturbance  in  cardiac  autonomic  tone - One of the mechanisms by which 
depression increases the risk of mortality in patients following MI is the adverse impact 
that depression has on cardiac autonomic tone and heart rate variability. Ventricular 
arrhythmias are responsible for most cases of sudden cardiac death in the post-MI 
period and are increased in patients with depressive co-morbidity (Carney, et al., 1999) 
(Gorman, et al., 2000). Decreased heart rate variability (HRV) increases the risk of 
ventricular arrhythmias and has recently been demonstrated in people with depression 
(Stein, et al., 2000). Moreover, when depression occurs following MI, the heart rate 
variability is further decreased, increasing the mortality risk in depressed patients with 
CVD even more (Carney, et al., 2001) (Pitzalis, et al., 2001). 
 
2.1.2.3 Disturbances  in blood clotting mechanisms - Increased platelet activation and 
thrombus formation is an important pathogenic feature in acute coronary syndromes 
(MI and unstable angina) with anti-platelet therapy being one of the contemporary 
mainstays of therapy (National Heart Foundation of Australia and the Cardiac Society of Australia 
and New Zealand, 2000). Substantial disturbance in platelet function occurs in depression 





events. Studies have demonstrated that platelet activation is increased in depressed 
individuals regardless of whether they have CVD (Laghrissi-Thode, et al., 1997) (Musselman, 
et al., 1996). More recently, evidence have revealed that depression is associated with 
hyperactive 5-hydroxytryptamine (5-HT) transporter2A receptor signal transduction 
system and increased responsiveness of platelets to serotonin (Schins, et al., 2003). 
Musselman et al. (Musselman, et al., 2000) reported that treatment with the selective-
serotonin-receptor reuptake-inhibitor (SSRIs), class of antidepressant, reduced the level 
of platelet activity in depressed patients to normal limits. Actually, depression increases 
platelet aggregation (Patrono, et al., 1997). Depressed ischemic heart disease patients 
showed elevated -thromboglobulin levels, increased plasma levels of platelet factor 4 
and increased expression of the platelet surface receptors for glycoprotein IIb/IIIa and 
P-selectin compared with non-depressed subjects (Laghrissi-Thode, et al., 1997). Finally it 
has been demonstrated a strong positive correlation of depression with high fibrinogen, 
PAI-1 and tPA-antigen suggesting an involvement of also fibrinolytic processes 
(Matthews, et al., 2007). All these factors could play a mediating role on the effect of 
depression in the development of CVD (Ranga, et al., 2003). 
 
2.1.2.4 Vascular endothelial dysfunction of the coronary arteries - Impaired vascular 
endothelial function is a hallmark of CVD has been found to occur in a variety of 
cohorts of depressed patients, including young and otherwise healthy individuals 
(Broadley, et al., 2002) (Rajagopalan, et al., 2001). Indeed, the role of inflammation in the 
pathogenesis of CVD is widely accepted. Low-grade chronic inflammation is predictive 
of MI and ischemic stroke. Endothelial dysfunction is a “critical intermediate 
phenotype” in the relationship between low-grade inflammation and CVD (Cleland, et al., 
2000). Several studies have reported on the consistent presence of a low-grade chronic 
inflammation in depression exemplified by mild to moderate elevations in circulating 
biomarkers, such as high-sensitivity CRP (hsCRP) and pro-inflammatory cytokines 
(Piletz, et al., 2009) (Dinan, 2008) (Dantzer, et al., 2008) (Leonard, 2010). Nitric oxide (NO) is the 
principal mediator of smooth muscle cell relaxation and contributes to overall vascular 
health. Its property as a vasodilator is well established. As levels of CRP increase, basal 
NO generation decreases significantly (Cleland, et al., 2000). Similarly TNF- reduces the 





decreased basal NO production. This in turn favors increased expression of cell-surface 
adhesion molecules for leukocytes and platelets inducing a pro-coagulant state. In 
summary, endothelial dysfunction is a crucial factor in the complex relationship 
between depression, low-grade chronic inflammation and CVD. 
 
2.1.2.5  Immune  system  activation - An increased sub-acute inflammatory immune 
response has been associated with depression and this may contribute to coronary artery 
atherosclerosis (Musselman, et al., 2000). Depressed patients have been shown to have 
elevated levels of inflammatory markers such as interleukin-6 (IL-6), C-reactive protein 
(CRP), tumor necrosis factor alpha (TNF), as well as shifts in the relative distribution 
of T and B lymphocytes (Miller, et al., 2000) (Suazrez, et al., 2003). These same markers are 
found in inflammatory reactions associated with unstable coronary artery plaques, 
which manifest as acute coronary syndromes. Hence, depression may either be a cause 
or an effect of the same inflammatory processes that cause CVD (Anisman, et al., 2002). If 
depression is the cause of the inflammatory process responsible for CVD, treatment of 
depression should reverse or at least reduce the inflammatory component underlying 
atherosclerosis. 
 
2.1.2.6 Neurotrophins – In addition to the previous mechanisms, neurotrophins may 
also play an important role in the connection between depression and cardiac outcomes. 
Depression has been strongly and consistently linked to low levels of BDNF (Hashimoto, 
2010) (Duman, et al., 1997) in the hippocampal neurons, and it is thought that BDNF 
signaling mediates the hippocampal neurogenesis that has been linked to depression 
recovery (Castren, et al., 2010). Moreover, two recent meta-analysis revealed that not only 
central but also BDNF serum levels are reduced in MDD patients compared with 
healthy controls and return to levels of the control group after antidepressant therapy 
(Brunoni, et al., 2008) (Sen, et al., 2008). BDNF plays also a key role in several physiologic 
processes important to cardiovascular health. Indeed, BDNF promotes angiogenesis and 
survival of endothelial cells. Moreover, in pathological conditions, i.e. during hypoxia, 
its expression is increased (Kim, et al., 2004). Finally, BDNF may be an important 
mediator of the previous noted HPA axis effects on depression and cardiovascular 





excessive glucocorticoid interferes with BDNF signaling (Kunugi, et al., 2010); therefore 
excess glucocorticoids may be associated with adverse outcomes via BDNF-mediated 
effects on endothelial cells. 
 
3 The neurotrophins 
The neurotrophins (NTs) comprise a family of at least four structurally related proteins- 
nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 
(NT-3) and neurotrophin-4/neurotrophin-5 (NT-4/NT-5). The first member of the 
neurotrophin family, NGF, was discovered in the early 1950s as a target-derived protein 
that promotes the survival and growth of sympathetic and sensory neurons during 
development (Cohen, et al., 1954) (McAllister, 1999). The establishment of the NT family 
came with the purification and characterization of BDNF from the pig brain (Barde, et al., 
1982). 
Since then, two other NTs have been identified in the mammalian brain: NT-3 and NT-4 
(Leibrock, et al., 1989). The genes encoding for these four NTs (ngf, bdnf, nt-3 and nt-4) 
produce 30- to 35-kDa pro-proteins; consisting of a preprodomain, a prodomain and a 
mature domain that are proteolytically cleaved to produce mature protein with a size of 
~13-kD (Barde, 1990) (Ibanez, 1998). Until recently, little consideration was paid to the NTs 
prodomain, which was thought to be only involved in protein folding and in regulation 
of NTs secretion (Suter, et al., 1991). The pro-NTs are greatly secreted in different tissues 
(Bruno, et al., 2006) (Fahnestock, et al., 2001) and have biological actions, different from those 
elicited by mature NTs (Lee, et al., 2001). Prodomain regions have highly conserved 
sequences across species and modifications on prodomain change the efficient 
trafficking of pro-NTs from the endoplasmic reticulum. The trafficking from the 
endoplasmic reticulum allows the majority of pro-NTs to undergo intracellular cleavage 
by furin-like proprotein convertases at the consensus site R-X-K/R-R (arginine-
unspecified aminoacid-lysine/arginine-arginine). The mature proteins form noncovalent 
symmetrical homodimers and are secreted into the extracellular environment (Chao, et al., 
2002) (Mowla, et al., 2001). In addition, also pro-NTs can be secreted from the cell and 
processed to mature NTs (Lee, et al., 2001). With the exception of NT-4/5, NTs are highly 
conserved from fishes to mammals (Hallbook, et al., 1991), thus sharing a similar molecular 





secreted proteins, which may serve the purpose of limiting their range of action 
(McDonald, et al., 1991); and 50% identity in primary structure (Mowla, et al., 2001). The 
structural hallmarks of NTs is a characteristic arrangement of the disulfide bridges, 
known as cysteine knot, also identified in other secreted proteins (McDonald, et al., 1993). 
The main actions mediated by the neurotrophins are the survival (McAllister, 1999), but 
also the differentiation (Waterhouse, et al., 2012) (Douglas-Escobar, et al., 2012), growth of 
neuronal processes (Bibel, et al., 2000), synaptic plasticity (McAllister, 1999) and apoptosis of 
neurons (Bibel, et al., 2000). 
 
3.1 Neurotrophins  sorting,  secretion  and  cleavage - After synthesis in the 
endoplasmic reticulum, (pro)neurotrophins need to be folded correctly, sorted into the 
constitutive or regulated secretory pathway, and transported to the appropriate 
subcellular compartment. Many non-neuronal cells, such as smooth muscle cells, 
fibroblast and astrocytes, may not express molecular components of the regulated 
secretory pathway and, therefore, secrete neurotrophins only constitutively. Regulated 
secretion is prevalent in neurons. Then, neurotrophins-containing secretory granules are 
transported to dendrites and spines, and are secreted postsynaptically. On the other 
hand, neurotrophin-containing large dense core vesicles undergo anterograde transport 
to axonal terminals. Some studies on BDNF secretion mechanisms have highlighted that 
the binary decision of sorting depends on both mature and pro-domain of neurotrophins. 
In fact, modeling and binding studies point to a critical interaction between the acidic 
residues in the BDNF motif and two basic residues in the sorting receptor 
carboxypepatidase E (CPE) (Cool, et al., 1995). Deletion of the Cpe gene in mice eliminate 
the activity-dependent secretion of BDNF from hippocampal neurons. In addition, the 
results of recent experiments indicate that the interaction of the pro-domain of BDNF 
with sortilin, a receptor that is localized mainly intracellularly (Petersen, et al., 1997) 
(Nielsen, et al., 2001), controls the mode of BDNF secretion (Figure 3) (Chen, et al., 2005). 
Sortilin is co-localized with BDNF in secretory granules of neurons, and interacts with 
two sub-regions, ‘box2’ and ‘box 3’, both of which are in the pro-domain of BDNF. 
When a truncated dominant negative form of sortilin (tSort) is expressed, there is a 





and in the regulated secretion (Chen, et al., 2005). These results indicate that in the absence 
of this motif, BDNF is sorted into the constitutive pathway. 
Like other secreted proteins, neurotrophins arise from precursor, proneurotrophins (30-
35 kDa), which are proteolytically cleaved to produce the mature proteins (12-13 kDa) 
(Seidah, et al., 1996). There are three ultimate fates of intracellular proneurotrophins: 
intracellular cleavage followed by secretion; secretion followed by extracellular 
cleavage; or secretion without subsequent cleavage. In particular, the 32-kDa proBDNF 
is the main form secreted from endothelial cells (Lee, et al., 2001), and culture neurons 
(Chen, et al., 2004) (Mowla, et al., 2001) (Mowla, et al., 1999). These findings indicate that 
mature BDNF is derived primarly from the cleavage of proBDNF by extracellular 
proteases, and that if uncleaved, the extracellular proBDNF might serve as an 
endogenous ligand. In addition, several matrix metalloproteinases (MMP), including 
MMP3 and MMP7, have been shown to cleave proNGF and proBDNF (Lee, et al., 2001). 
However the most significant protease that cleaves proneurotrophins is the serine 







Figure 3 Example of neurotrophin sorting and releasing. First synthetized in the endoplasmic reticulum 
(ER), proBDNF (precursor of BDNF) binds to intracellular sortilin in the Golgi to facilitate proper 
folding of the mature domain. A motif in the mature domain of BDNF bind to carboxypeptidase E (CPE), 
an interaction that sorts BDNF into large dense core vesicles. In the absence of this motif, BDNF is sorted 
into the constitutive pathway. After the binary decision of sorting, BDNF is transported to the appropriate 
site of release, either in dendrites or in axons. Because, in some cases, the pro-domain is not cleaved 
intacellularly by furin or protein convertases, proBDNF can be released by neurons. Extracellular 
proteases, such as metalloproteinases and plasmin, can subsequently cleave the pro-region to yeld mature 
BDNF (mBDNF). 
3.2  Neurotrophins  receptors - Neurotrophins exert their effects through two 
classes of  transmembrane receptor proteins: high affinity tyrosine kinase receptors 








Figure 4 The actions of neurotrophins are mediated by two principal transmembrane-receptor signaling 
systems. Each neurotrophin receptor- TrkA, TrkB, TrkC and the p75 neurotrophin receptor (p75 NTR)- is 
characterized by specific affinities for the neurotrophin. 
 
Trk receptor family - The Trk family of receptor tyrosine kinases, identified in 
mammals, derives its name from the oncogene that resulted in its discovery (Huang, et al., 
2003). This oncogene was isolated in gene transfer assays from a carcinoma and, when 
cloned, was found to consist of the first seven of eight exons of non-muscle 
tropomyosin fused to the transmembrane and cytoplasmic domains of a novel tyrosine 
kinase. 
The TrkA protooncogene was first identified as a NGF receptor, followed by TrkB and 
TrkC. NGF is the preferred ligand for TrkA, BDNF and NT-4/5 are preferred for TrkB 
and NT-3 for TrkC. Trk receptors share a common structural organization of their 
extracellular domains that clearly distinguishes them from other receptor tyrosine 
kinases (Schneider, et al., 1991). Immediately following the cleaved signal sequence there is 
an array of three leucine-rich 24-residues motifs flanked by two cysteine clusters. Two 
C2-type immunoglobulin-like domains are adjacent to these structures, which are 





tyrosine kinase domain plus several tyrosine-containing motifs similar to those present 
in other receptor tyrosine kinases. Like other receptor tyrosine kinases, phosphorylation 
of cytoplasmic tyrosines in Trk receptors regulates tyrosine kinase activity and provides 
phosphorylation-dependent recruitment sites for adaptor molecules and enzymes that 
mediate initiation of intracellular signaling cascades (Huang, et al., 2001) (Bibel, et al., 2000) 
(Patapoutian, et al., 2001) (Sofroniew, et al., 2001) (Kaplan, et al., 2000). The N-termini of 
neurotrophins are important in controlling specificity, and the structure of this region is 
reorganized upon binding to a Trk receptor. Interactions with Trk receptors also modify 
neurotrophin structures in other regions. This deformability appears important for 
permitting some neurotrophins to activate more than one type of Trk receptor (Huang, et 
al., 2003). 
 
Splice variants of Trk receptors - Splice variants have been described for all three Trk 
receptors. These receptor molecules have either deletions in the extracellular domain or 
intracellular truncations including the tyrosine kinase domain. Insert variants of TrkA 
and TrkB were found to influence ligand specificity. However, their biological roles 
remain unclear. The truncated TrkB receptor isoforms, designated as T1 and T2, contain 
short intracellular domains (Klein, et al., 1990). They are up-regulated during early 
postnatal development and predominate over full-length TrkB in the adult brain (Fryer, et 
al., 1996). These truncated receptors are often expressed in non-neuronal cells that do not 
express full-length TrkB. (Klein, et al., 1990). They internalize BDNF and may restrict its 
availability (Biffo, et al., 1995). 
 
P75NTR receptor - P75 was the first member to be molecularly cloned of a large family 
of receptors, which includes both TNF receptors, Fas, CD40 and ~15 other members. 
The defining motifs of this receptor family are cysteine repeats in the extracellular 
domain, which form the ligand-binding domain. None of these receptors exhibits any 
intrinsic catalytic activity, and they signal by associating with, or dissociating from, 
cytoplasmic interactors. Indeed, there are several protein association motifs in the 
cytoplasmic domain of p75. It is distantly related to the so-called death domain of other 
members of the family. All neurotrophins bind to p75 with an affinity of ~10-9 M, that is 





11 M). In addition to the major transcript encoding the full-length receptor, a minor 
transcript exist encoding a protein truncated in the extracellular domain that has lost its 
ability to bind neurotrophins (Dechant, et al., 1997). Anyway about 40% of the mutant 
animals die during embryogenesis, apparently from defects in the formation of blood 
vessels (Bibel, et al., 2000). Like several other members of its family, p75 is processed by 
proteolysis, and relatively high levels of a soluble form of p75 have been measured in 
various body fluids (Zupan, et al., 1989). 
 
3.3 Neurotrophins  signaling - Binding of the neurotrophins to the Trk receptors 
leads to receptors tyrosine phosphorylation. Ligand-induced dimerization results in the 
phosphorylation of specific tyrosine residues, located in the so-called activation loop of 
the tyrosine kinase domain. Phosphorylation of these residues leads to an open 
conformation of the receptor resulting in trans-phosphorylation and allowing the access 
of substrates to the kinase. Phosphotyrosine residues on Trk receptors then act as 
docking sites for adapter molecules (Bibel, et al., 2000). Three main signaling cascades are 
activated by the Trk receptors and their substrates. First the activation of 
Ras/Raf/MEK/MAPK pathway. Inhibition of Ras activity, decreases survival of most, 
but not all, populations of sympathetic neurons (Borasio, et al., 1993) (Nobes, et al., 1995). 
Second, the activation of PI3K, implicated in neuronal survival via the activation of 
PKB/AKT kinase. Third, the association of PLC- with Trk, that regulates intracellular 
Ca2+ levels and protein kinase C activity via cleavage of the substrate PIP2 to DAG and 
IP3, pathway that seems important in neurotrophin-mediated neurotrophin release and 
in synaptic plasticity (Bibel, et al., 2000). 
Whereas it is now clear that p75 transduces signals following neurotrophin binding, the 
function of this receptor varies considerably depending on the cellular context in which 
it is expressed. The first indication for the signaling function of p75 was the finding that 
p75 mediates sphingomyelin hydrolysis and production of ceramide following 
neurotrophin binding (Dobrowsky, et al., 1994) (Dobrowsky, et al., 1995). p75 seems to interact 
with caveolin. Caveolae are presumably the site of neurotrophin-induced sphingomyelin 
hydrolysis. Ceramide production is known to follow TNF binding to its receptor and to 





Trk receptors, NF-kB activation was observed following the addition of NGF (Carter, et 
al., 1996). It appears that activation of NF-kB prevents cell death. (Liu, et al., 1996) 
Beyond the activation of NF-kB that seems to mediate cell survival, there are also clear 
indications that p75 activation by neurotrophins causes programmed cell death. Indeed, 
the original finding that p75 could mediate neuronal apoptosis in a neural cell line 
(Rabizadeh, et al., 1993) has, over the past several years, been extended to a large number of 
primary neural cells. Still controversial, however, is the role of p75 in regulating 
survival of some neural cell lines. 
Recent studies allowed, neverthless, to conclude that the apoptotic actions of p75 is 
ligand-dependent (Majdan, et al., 1997), that signals apoptosis occur in a Trk-independent 
manner (Bredesen, et al., 1998) (Vaillant, et al., 1999) and that Trk activation silences p75 
apoptotic signaling (Aloyz, et al., 1998) (Yoon, et al., 1998), leaving other p75 pathways 
‘intact’. In particular p75 mediates apoptosis signaling during neural injury and during 
development (Yoon, et al., 1998). Cell death signaling involved are JNK-p53-Bax (Vaillant, 
et al., 1999), NRIF (neurotrophin receptor-interacting factor) (Casademunt, et al., 1999), 
TRAF (tumor necrosis factor receptor-associated factor) (Khursigara, et al., 1999) and two 
novel finger motif proteins SC-1 (Schwann cell factor-1) (Chittka, et al., 1999) and 
NRAGE (neurotrophin receptor-interacting MAGE [melanoma antigen gene] 
homologue) (Salehi, et al., 2000) (Kaplan, et al., 2000). 
 
3.4 Distribution  and  expression of  neurotrophins  and  their  receptors - 
Through the differential expression and cellular localization of their receptors, 
neurotrophins can elicit diverse cellular functions in different types of neurons and at 
different cellular loci (Hyungju, et al., 2013). Indeed in contrast to other signaling system, 
the neurotrophins are not ubiquitously expressed. In addition, the neurotrophins are 
primarly localized in the target areas innervated by the responsive peripheral nervous 
system (PNS) axons (Davies, 1994). BDNF, NT-3 and NT-4/5 and their receptors, TrkB 
and TrkC, are widely and specifically distributed in the CNS, whereas NGF and its 
receptor TrkA expression is restricted to defined areas of the CNS such as striatal and 
basal forebrain cholinergic neurons. BDNF and NT-3 and their cognate receptors, TrkB 
and TrkC, are particularly highly expressed in the cerebellum, hippocampus and 





(McAllister, 1999). TrkC is also typically expressed early in development (Tessarollo, et al., 
1993). In situ hybridization studies further indicate that full-length, kinase-containing 
forms of TrkB and TrkC are expressed, and often co-expressed, on most CNS neurons 
but not on non-neuronal cells. In contrast, truncated, non-catalytic forms of both TrkB 
and TrkC are found in both neurons and glial cells (McAllister, 1999). P75 is co-expressed 
with the Trk receptors in many neuronal populations (Chao, et al., 1995). During postnatal 
development, p75 is downregulated in most parts of the CNS but is rapidly induced 
after nerve lesion or seizure (Roux, et al., 1999). Finally, p75 is also expressed by different 
types of cells by the time they become postmitotic cells and/or migrate (Farinas, et al., 
1998). 
Neurotrophins and their receptors are not only expressed in neuronal tissues but also in 
non-neuronal tissues and various cell types such as developing heart (Clegg, et al., 1989), 
spleen (Yamamoto, et al., 1996), atherosclerotic vessels (Donovan, et al., 1995), macrophages 
(Barouch, et al., 2001), lymphocytes (Kerschensteiner, et al., 1999), endothelial cells (Nakahashi, 
et al., 2000) and vascular smooth muscle cells (Donovan, et al., 1995). For example, TrkA 
receptor is expressed by monocytes and its expression decreases during their 
differentiation into macrophages (Ehrhard, et al., 1993). TrkB receptor, instead, is 
expressed in muscle, heart and the vasculature (Scarisbrick, et al., 1993) (Timmusk, et al., 1993) 
(Donovan, et al., 1995) (Hiltunen, et al., 1996). In pathological states, TrkB expression is 
induced in neointimal vascular smooth muscle cells of the adult rodent and human aorta 
following vascular injury (Donovan, et al., 1995), while its haploinsufficiency is associated 
with a decrease in ApoE-null mice, in lesion development in the advanced stages of 
atherogenesis (Kraemer, et al., 2005). All together these data suggest that NTs have diverse 
roles even in non-neuronal tissues. 
 
3.5 Role of neurotrophins in cardiovascular system – Role of neurotrophins 
in cardiovascular development and adult cardiovascular system. NTs and their 
receptors are expressed during the developing heart and vessels (Bernd, et al., 2004) 
(Scarisbrick, et al., 1993). In particular, BDNF deficiency reduces endothelial cell-cell 
contact in the mouse embryonic heart, thus leading to intraventricular wall hemorrhage 
and depressed cardiac contractility (Donovan, et al., 2000). Similarly, TrkB-/- mice show a 





the developing heart (Wagner, et al., 2005). NT-3-/- mice develop abnormalities of the great 
vessels (Donovan, et al., 1996) (Tessarollo, 1998). Moreover, genetic deficiency of either NT-
3 or TrkC impaired cardiac morphogenesis in mice (Donovan, et al., 1996) (Tessarollo, et al., 
1997). Some of these developmental defects appeared as early as embryonic day (Arevalo, 
et al., 2006) (Anand, et al., 1996), which is before the onset of cardiac innervation in mice, 
thus suggesting the existence of a direct control of NTs on cardiovascular development 
(Tessarollo, 1998). Also p75NTR is present in endothelial cells and vascular smooth muscle 
cells of large blood vessels during prenatal development (Von Schack, et al., 2001). Indeed, 
global null mice lacking all p75NTR (p75NTRExonIV-/-) show thinner wall and increased 
lumen diameter of the dorsal aorta; moreover, many p75NTRExonIV-/- embryos show 
vascular ruptures and cell leakage (Von Schack, et al., 2001). 
It has been demonstrated that neurotrophins play key role also in adult cardiovascular 
system. Specifically NTs are expressed in endothelial cells (Kim, et al., 2004), where 
promote angiogenesis processes (Santos, et al., 1991) (Raychaudhuri, et al., 2001) (Cantarella, et 
al., 2002) (Nakamura, et al., 2006) (Kermani, et al., 2005) (Caporali, et al., 2009), in vascular smooth 
muscle cells (Scarisbrick, et al., 1993), where regulate chemotactic action (Donovan, et al., 
1995), and in cardiac myocytes (Hohn, et al., 1990) (Maisonpierre, et al., 1990) (Selby, et al., 1987) 
(Timmusk, et al., 1993), where favor prosurvival signaling (Caporali, et al., 2008). 
 
Role of neurotrophins in non-neuronal pathology. Considering the actions mediated 
by NTs, it has been demonstrated their link to some pathologies. Being strong 
promoters of angiogenesis and able to activate VEGF-A and metalloproteases, NTs 
contribute to the growth and diffusion of cancers (Bergers, et al., 2000) (Duffy, et al., 2008) 
(Jain, et al., 2007) (Nico, et al., 2008) and are associated with chronic inflammation 
(Raychaudhuri, et al., 2001) (Raychaudhuri, et al., 2004) (Rihl, et al., 2005). Notably, NTs are 
recruited also in inflammation after MI (Cai, et al., 2005), are expressed in vascular smooth 
muscle cells of human atherosclerotic plaque (Kraemer, 2002) where may contribute to 
plaque instability (Ejiri, et al., 2005) and finally, their expression is dramatically 
upregulated by arterial balloon injury (Donovan, et al., 1995). 
 
3.5.1  Brain‐derived  neurotrophic  factor  (BDNF)  and  its  cardiovascular 





revisited extensively (Timmusk, et al., 1993) (Aid, et al., 2007) (Liu, et al., 2005). Briefly, the 
human BDNF gene consists of several 5’ exons with independent promoters. The 3’ 
coding exon (exon IX) contains the sequence that codes for the pro-BDNF protein 
(Figure 5) (Boulle, et al., 2012). 
 
 
Figure 5 Human BDNF gene structure. Exons are represented as boxes and the introns as lines. Numbers 
of the exons are indicated in roman numerals and the size of exons and introns is indicated in arabic 
numerals. The 3´ coding exon (exon IX) contains two polyadenylation sites (poly A). The red box 
represent the start codon ATG that mark the initiation of transcription. The green box shows the region of 
exon IX coding for the pro-BDNF protein. Some exons, like exon II and IX, contain different transcript 
variants with alternative splice-donor sites (A, B, C, D). 
BDNF is enriched in the central nervous system and is very important for the fetal 
development of the central nervous system, neuron plasticity and the preservation of 
memory in adulthood (DeFreitas, et al., 2001) (Chao, 2003). The expression or secretion of 
BDNF in the central nervous system is altered in neurodegenerative and psychiatric 
diseases (Pezet, et al., 2004) (Huang, et al., 2003) (Qian, et al., 1998) and consequently is 
considered a good target for the aetiology of MDD (Duman, et al., 1997) (Eikelis, et al., 2006). 
It has been demonstrated that BDNF is also produced in non-neuronal tissues. Low 
levels of BDNF mRNA and BDNF are detected in the thymus, liver, spleen, heart and 
lung (Ernfors, et al., 1990) (Katoh-Semba, et al., 1997) (Maisonpierre, et al., 1990) (Maisonpierre, et al., 
1991). Lymphocytes and monocytes produce BDNF (Edling, et al., 2004) (Kerschensteiner, et 
al., 1999) (Schulte-Herbruggen, et al., 2005) and eosinophils utilize self-produced BDNF via 
the autocrine system to survive, evoking and extending the allergic reaction (Nockher, et 
al., 2005) (Raap, et al., 2005). Furthermore, BDNF also contributes to tumor cell growth and 
functions as an angiogenesis factor in circulating blood (Pearse, et al., 2005) (Yang, et al., 
2006). The heterogenous distribution of BDNF, suggest its other functions, often not 
strictly related to neurological area. 
Firstly, platelets contain abundant BDNF at a level comparable to that of the serum 





times higher than that of plasma because platelets release BDNF during the clotting 
process (Radka, et al., 1996) (Fujimura, et al., 2006) (Lommatzsch, et al., 2005) (Karege F, 2005a). 
From those findings, it is thought that platelets are important cells to store BDNF 
secreted from other tissues. Tamura et al. demonstrated that BDNF release from 
platelets occurs after stimulation with PAR1 activation, human platelets have two 
distinct pools of BDNF, in the -granules (Lorgis, et al., 2009) (Pliego-Rivero, et al., 1997) and 
cytoplasm and BDNF contained in -granules is that release after stimulation, not that 
of the cytoplasm (Tamura, et al., 2011). The origin of platelet BDNF is still elusive. It was 
suggested that BDNF is taken up into platelets through an uncharacterized transport 
mechanism (Fujimura, et al., 2006), or translated in platelets from mRNA derived from 
megakaryocytes (MK) (Tamura, et al., 2012) or taken up from the circulation. However, 
debate is the ability of megakaryocytes to express and/or produce BDNF. In fact, MEG-
01, a megakaryocytic cell line, neither express BDNF and lack the ability to produce 
BDNF under autonomous proliferating conditions in absence of cytokines (Fujimura, et al., 
2006); in contrast, MEG-01 stimulated/differentiated with thrombopoietin (TPO) show a 
great ability to produce BDNF (Tamura, et al., 2012). However, since the release of BDNF 
from platelets is strictly correlated to the release of VEGF, it has been supposed a pro-
angiogenic function of BDNF, as confirmed by other studies (Yang, et al., 2006) (Donovan, 
et al., 2000) (Kermani, et al., 2005) (Kim, et al., 2004). 
Secondly, BDNF can modify inflammation pattern; indeed the BDNF receptor, TrkB, is 
increased in the heart of aging rodent; moreover functional studies revealed that age-
associated alterations in cardiac BDNF-mediated pathways could enhance inflammation 
and increase MI in the aging heart (Cai, et al., 2005). Moreover, increased inflammation is 
associated to a greater infiltration of mononuclear cells. Remarkable, the 
intramyocardial administration of BDNF induces an increase in inflammation and 
macrophages activity (Lorgis, et al., 2009). Further, BDNF favours macrophage 
phagocytosis and promotes the release of some inflammatory cytokines, such as 
interleukin (IL)-1 (Asami, et al., 2006)Moreovermodifications in the expression and 
production of BDNF have been detected in both chronic inflammatory diseases and in 
atherosclerosis (Chaldakov, et al., 2001) (Kerschensteiner, et al., 1999). In particular, it has been 
shown that BDNF and its receptor TrkB are strongly expressed in atherosclerotic 





animal models. These increases are associated with mononuclear cell infiltration 
(Kermani, et al., 2007) and activation of matrix-degrading proteases MMP-2 and MMP-3, 
and stimulation of uPA and PAI-1 production by endothelial cells (Pepper, 2001) (Sun, et 
al., 2006). BDNF/TrkB activation pathway seems to be involved in the formation of 
atherosclerotic plaque and in the revascularization of ischemic tissues, playing a 
complex role in the cardiovascular dysfunction and in angiogenic processes. Indeed, 
Kraemer et al. (Kraemer, et al., 2005) show that the decreased expression of neurothrophin 
TrkB receptor reduces lesion size in the apolipoprotein E-null mutant mouse, whereas 
Kermani et al. (Kermani, et al., 2007), in a model of peripheral ischemia, show that BDNF 
enhances capillary formation increasing local TrkB-expressing endothelial cells and the 
recruitment of subpopulation of myeloid cells, which may contribute to vessel 
formation or stabilization.  
BDNF has been implicated in glucose and lipid metabolism, energy homeostasis and in 
metabolic syndrome (Geroldi, et al., 2006) (Han, et al., 2008) (Saito, et al., 2009). Actually 
patients heterozygous for BDNF deletions showed higher Body Mass Index (BMI) z 
score throughout childhood and by 10 years of age, 100% of the patients are obese (Han, 
et al., 2008). Similarly, individuals with obesity and type 2 diabetes have low circulating 
levels of BDNF (Krabbe, et al., 2007), as well as there is an inverse association between the 
peripheral BDNF concentration and BMI in children and adults (Lommatzsch, et al., 2005). 
Studies carried out on murine models have supported all these observations. In fact, 
both heterozygous for targeted disruption of BDNF (BDNF+/- mice) (Kernie, et al., 2000), 
and the reduction in the expression of TrkB (in partial KO mice) (Xu, et al., 2003) lead to 
obesity in mice as consequences of increased food intake. Intracerebroventricular (ICV) 
infusion of BDNF into BDNF+/- mice normalizes food intake, body weight and activity, 
suggesting a physiological role of BDNF in regulating food intake (Rothman, et al., 2012). 
Considerable amount of research effort has been devoted to understand the role of 
BDNF in the pathogenesis and/or recovery of major types of cardiac diseases. BDNF is 
essential for the development of the autonomic nervous system (ANS), in particular in 
the formation of synaptic connectivity with peripheral target and for the survival of 
arterial baroreceptors during vascular innervation (Brady, et al., 1999). Recent findings 
indicate that BDNF plays a major role in ANS control of cardiovascular function in 





both exercise and dietary energy restriction, modulate ANS with consequent decreased 
heart rate and increased heart rate variability (Rosenwinkel, et al., 2001) (Wan, et al., 2003b). 
Finally, BDNF+/- mice, which exhibit a 50% in BDNF mRNA, have significantly 
elevated heart rates compared to WT mice. Further, when exposed to restraint stress, 
BDNF+/- mice fail to elevate their heart rate to WT levels, indicating an impaired 
cardiovascular stress response (Rothman, et al., 2012). 
However, while some studies have demonstrated a reduction of NGF expression in 
human atherosclerotic plaques (Chaldakov, et al., 2001), other have shown marked 
expression of BDNF in the atheromatous intima and adventitia, macrophages and 
smooth muscle cells in atherosclerotic coronary arteries in people with unstable angina 
(Ejiri, et al., 2005). In particular, the stimulation with recombinant BDNF significantly 
enhanced oxidative stress in cultured human coronary artery smooth muscle cells, 
suggesting that BDNF is involved in the mechanism of oxidant injury and supporting 
the observation that increased coronary levels of BDNF was linked to platelet activation 
and inflammatory response (Lorgis, et al., 2009). 
In addition, circulating levels of BDNF are proposed as predictor risk factor for CVD. 
Plasma BDNF level is reported to decrease in subjects with acute coronary syndrome 
(Manni, et al., 2005). In contrast, significantly greater serum BDNF levels are found in the 
coronary sinus blood samples in subjects with unstable angina compared to those with 
stable angina or healthy controls and in patients with myocardial infarction, and these 
levels correlated positively with soluble P-selectin, an index of platelets activation (Ejiri, 
et al., 2005) (Lorgis, et al., 2009). Recently, plasma BDNF levels have been inversely 
associated with the levels of triglyceride, LDL-cholesterol and fibrinogen, male sex and 
age and positively with high-density lipoprotein cholesterol level and platelet count in 
people with angina pectoris. Interestingly, plasma BDNF level was as an independent 
predictor of 4-year coronary and all-cause mortality, indicating that low plasma BDNF 
may be associated with future coronary events and death in these patients (Jiang, et al., 
2011). 
At the light of these data, it is possible conclude that BDNF regulates many 






3.5.1.1 BDNF Val66Met polymorphism - The recent discovery of a single-nucleotide 
polymorphism (SNP) in the bdnf gene (Val66Met), found only in humans, leading to a 
methionine (Met) substitution for a valine (Val) at codon 66 in the pro-domain (Figure 




Figure 6 Structure of the human BDNF gene. The green box shows the region of exon IX coding for pro-
BDNF gene protein, including the rs6265 genetic variant implicated in the Val66Met polymorphism. 
This polymorphism is common in human population with an allele frequency of 20 to 
30% in Caucasian population (Schimizu, et al., 2004). Human heterozygous for the Met 
allele have smaller hippocampal volumes (Bueller, et al., 2006) (Pezawas, et al., 2004) (Szeszko, 
et al., 2005) and perform poorly on hippocampal-dependent memory tasks (Hariri, et al., 
2003) (Egan, et al., 2003). The mechanisms that contribute to alter BDNFMet function have 
been studied in neuronal culture systems. The distribution of BDNFMet to neuronal 
dendrites and its activity-dependent secretion are decreased (Egan, et al., 2003) (Chen, et al., 
2005) (Chen, et al., 2004). These trafficking abnormalities are likely to reflect impaired 
binding of BDNFMet to a sortilin, a sorting protein, that interacts with BDNF in the 
prodomain region that encompasses the Met substitution (Chen, et al., 2005). This 
polymorphism has been associated to an altered susceptibility to various 
neuropsychiatric diseases, including Alzheimer’s disease (Ventriglia, et al., 2002) Parkinson 
disease (Momose, et al., 2002), schizophrenia (Neves-Pereira, et al., 2005) (Rosa, et al., 2006), 
schizoaffective disorder (Lencz, et al., 2009) and bipolar disorder (Sklar, et al., 2002) (Muller 
DJ, 2006). The effect of the polymorphism on the circulating blood of BDNF is still 
unclear and controversial. Some studies did not find any difference among plasma 
levels in Met/Met and Val/Val or Val/Met subjects (Tramontina, et al., 2007) (Karege F, 
2005a) (Terracciano, et al., 2010); while other groups demonstrated that the polymorphism is 
associated to increased levels of serum BDNF (Lang, et al., 2009). However, some studies 





levels and more specifically a down-regulation of mature form of the neurotrophin 
(mBDNF), while plasma BDNF levels are often unchanged (Bocchio-Chiavetto, et al., 2010), 
indicating an altered release of BDNF. 
Some studies have demonstrated the existence of the link between the polymorphism 
and cardiovascular diseases. A recent finding has demonstrated that BDNF Val66Met 
polymorphism is associated with unstable angina pectoris (UAP) in the population of 
Han Chinese, and it seems that the BDNFMet/Met genotype has a protective effect on the 
occurrence of UAP (Jiang, et al., 2009). On the other hand, Bozzini et al. (Bozzini, et al., 2009) 
suggest an involvement of the Met/Met genotype in the pathogenesis of CAD, 
associated with depression, in women, arguing a protective role of Val/Val genotype 
against CAD and against CAD associated with depression. 
Finally, Alexander and collegues highlighted a significant effect of the BDNF 
Val66Met polymorphism on hypothalamic-pituitary-adrenal (HPA)-axis reactivity to a 
standardized laboratory stress task in healthy male adults, pointing to an attenuated 
cortisol response in met-allele carriers when compared to subjects homozygous for the 
val-allele. Moreover, the same picture emerges with regard to heart rate reactivity as an 
indicator for the sympathetic activation. Based on these findings, the authors tempt to 
speculate that reduced activity-dependent secretion of BDNF in met-allele carriers 
results in an attenuated BDNF release to endocrine and cardiovascular stressful 
situations (Alexander, et al., 2010). 
In conclusion, in consideration of the heterogeneity of data available in literature, the 





Evidence suggests a strong link between neurotrophin and cardiovascular disease 
(CVD) (Caporali, et al., 2009). 
The brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family of 
growth factors that promotes neuronal survival, differentiation and maintenance 
(Donovan, et al., 2000), is involved in the pathogenesis of different neurodegenerative 
diseases (Zuccato, et al., 2009). BDNF and its receptor, the tyrosine receptor kinase B 
(TrkB), are also expressed in non-neuronal cells, such as activated macrophages and 
lymphocytes (Nakahashi, et al., 2000), platelets (Fujimura, et al., 2006) (Karege F, 2005a), 
endothelial and vascular smooth muscle cells (Donovan, et al., 2000). BDNF plays a critical 
role in regulating both vascular development (Kermani, et al., 2007) and response to injury 
(Lewin, et al., 1996). 
Indeed, it is enriched in atheromatous intima and around adventitial vasa vasorum, 
while hardly detectable in non-atherosclerotic arteries (Ejiri, et al., 2005). Intriguingly, 
reduced levels of BDNF have been associated with increased coronary events and 
mortality in patients affected by acute coronary syndrome (Manni, et al., 2005). 
An amino acid substitution at codon 66 (BDNF Val66Met) that affects BDNF 
availability and function (Chen, et al., 2004), is related to stress vulnerability (Ventriglia, et 
al., 2002) (Momose, et al., 2002) (Sen, et al., 2003) (Neves-Pereira, et al., 2002) and recently it has 
been suggested to be linked to CVD (Bozzini, et al., 2009) (Jiang, et al., 2009). No information 
is available on a role of BDNF in thrombosis. We hypothesize that a genetic variant of 
BDNF gene, underlie an increased susceptibility to thrombotic events. In particular we 
focused on analysing the different actors involved in the thrombotic events: the 
coagulation cascades, platelets and vessel wall. 
To achieve this goal, the experiments have been carried out in mice generated with a 
variant BDNF mouse (BDNFMet/Met) that reproduces the phenotypic hallmarks in 
humans with the variant allele. BDNFMet/Met mice, considered a good model of 
depression, when placed in conflict settings (Chen, et al., 2004), display increased anxiety-
related behaviours, caused by a reduction of its trafficking; thus representing not only a 
good model to understand the role of neurotrophins in thrombosis but also to clarify the 









The physiological relevance of BDNF Val66Met mutation on thrombosis was studied in 
BDNF Val/Val (wild type) and BDNF Met/Met mice, both genders and age of 10-12 
weeks. In particular, we used two different thrombosis models: a) the carotid artery 
FeCl3 (10%) injury model and b) the thromboembolism model. In the carotid artery 
injury model the thrombus formation was evaluated as flow variation, monitored during 
a 30 minutes-period after the application of the stimulus. It was considered a stable 
occlusion when we observed a decrease in flow of ≥90% from baseline for ≥5 minutes, 
during which time the flow did not change by > 1% of baseline per second. No 
significant difference in terms of basal levels of blood flow was noted between mouse 
genotypes (Val/Val: 0.97 ± 0.01 and Met/Met: 0.96 ± 0.04 ml/min; p=0.42). Topical 
application of FeCl3 induced a stable clot occlusion in 83.3% of Met/Met mice. In 
contrast, all Val/Val mice developed only a partially carotid artery occlusion (48%) 
within the same 30-minutes observation period. In particular, in Met/Met mice, blood 
flow was dramatically reduced compared with Val/Val mice within 10 minutes by the 
application of FeCl3 with a markedly shorter carotid occlusion time (Figure 1A and B), 
indicating an increased propensity to thrombosis in these animals compared to Val/Val 
mice. The strong differences observed in terms of carotid arterial thrombus formation 
between Val/Val and Met/Met mice were further confirmed by histological analysis 






















































Figure 1 Ferric chloride-induced thrombosis. A) Blood flow was monitored for a period of 30 minutes 
after application of ferric chloride on the carotid artery of Val/Val and Met/Met mice; B) mean occlusion 
time of Val/Val (open circles) and Met/Met (black squares) mice; C) histological analysis of thrombi 
isolated from Val/Val and Met/Met mice (n=6-7 mice per group). Data shown are mean ± SEM. 
The increased thrombotic phenotype of Met/Met mice was also confirmed in a 
pulmonary thromboembolism model, in which platelet-rich clots are triggered by rapid 
intravenous administration of a mixture of collagen and epinephrine. Mice were 
observed for 15 minutes and the time of cessation of breathing stasis recorded. The 
percentage of mortality in Met/Met mice, within 15 minutes after collagen/epinephrine 
injection, was significantly higher compared with their Val/Val littermates (Val/Val: 



































Figure 2 Thromboembolism model. Percentage of survival of Val/Val and Met/Met mice after infusion of 
a collagen and epinephrine mixture (p= 0.02; n=6 mice per group). Data shown are mean ± SEM. 
 
These results indicate that BDNF Val66Met polymorphism predisposes to thrombotic 
events in vivo. 
 
2  Blood  cell  counts  and  platelets  parameters  in  Val/Val  and 
Met/Met mice 
Blood cell counts from Val/Val and Met/Met mice were performed. Similar number of 
red blood cells was counted in the two groups of animals (Table 1). In contrast, very 
higher number of platelets (Table 1) was measured in Met/Met mice. Moreover, 
Met/Met mouse platelets have similar size (Table 1), but a significant, even if mild, 
higher percentage of reticulated platelets compared to Val/Val mice (Table 1). 
In addition, Met/Met mice showed a greater number of circulating leukocytes compared 
to Val/Val mice (Table 1). Considering the heterogeneity of leukocyte populations and 
their different biological roles, we performed counts of neutrophil granulocytes, 
monocytes and lymphocytes on whole blood of Val/Val and Met/Met mice. We 
observed that neutrophil (Table 1) and monocyte (Table 1) counts were significantly 
higher in Met/Met mice than in control mice, while lymphocytes were similar in the two 






 Val/Val Met/Met 
Erythrocytes (106/l) 15.3 ± 0.8 15.3 ± 0.8 
Leukocytes (#/l) 2523.0 ± 140.1 3810.0 ± 253.4*** 
Neutrophil granulocytes (#/l) 408.3 ± 47.4 706.5 ± 109.6* 
Monocytes (#/l) 48.3 ± 3.1 184.0 ± 34.0* 
Lymphocytes (#/l) 2168.0 ± 154.4 2998.0 ± 473.6 
Platelets N° (103/l) 1046.0 ± 38.5 1296.0 ± 53.5*** 
MPV fL 6.5 ± 0.06 6.5 ± 0.2 
% reticulated platelets 13.5 ± 0.6 15.4 ± 0.8* 
Table 1 Effect of BDNF Val66Met polymorphism on blood cell counts and platelets parameters. MPV: 
mean platelet volume (n=6-12 mice per group). Data shown are ± SEM. *p<0.05; **p<0.01; ***p<0.001. 
 
The high platelets number associated with increased leukocytes number suggest a pro-
thrombotic and pro-inflammatory phenotype of Met/Met mice. 
 
3  Evaluation  of  hemostatic  system  in  Val/Val  and  Met/Met 
mice 
To evaluate a possible alteration in the hemostatic system of Met/Met mice, rotation 
thromboelastography (ROTEM®) analysis were performed. This method assesses the 
combined influence of circulating plasmatic and cellular (platelets, red blood cells, 
leukocytes) elements on clot formation, including platelet function and fibrin formation 
in whole blood, evaluating the viscoelasticity of clot during all phases of its formation. 
In particular, we considered only some parameters obtained from the 
thromboelastographic trace, i.e. coagulation time (CT), clotting formation time (CFT), 
maximum clot firmness (MCF) and maximum clot elasticity (MCE). 
In addition, we carried out specific tests to evaluate the activity of coagulation factors 
and of Tissue Factor (TF), the functionality of platelets and fibrinogen. 
 
Recalcification test (NATEM), induced by the addition of high concentration of CaCl2, 
showed that CFT was significantly shorter in Met/Met mice and that MCF and MCE in 




CT was almost the same between the two different groups of mice. In conclusion, 
NATEM test provides evidence that whole blood clot stability and elasticity is increased 
in Met/Met mice compared to Val/Val mice and it suggests an alteration in platelets and 
fibrinogen activity in homozygote transgenic Met/Met mice. 
 
Two specific thromboelastographic tests to evaluate the contribution of extrinsic 
(EXTEM) and intrinsic (INTEM) pathways of the coagulation were performed. From 
these tests emerged that: CT was similar in the two groups of animals analyzed in both 
tests, suggesting unchanged coagulation factors functionality. In contrast, CFT was 
shorter in Met/Met mice only in the EXTEM test, indicating altered platelets and/or 
fibrinogen functionality specifically linked to the activation of extrinsic pathway. 
However, statistical differences in terms of MCF and MCE were detected both in 
EXTEM and INTEM tests. In fact, blood from Met/Met mice showed a greater MCF 
and MCE than Val/Val mice (Table 2).  
These results show that Met/Met mice form greater and more stable clot, due probably 
to higher functionality of platelets and fibrinogen. 
 
 NATEM INTEM EXTEM 
 Val/Val Met/Met Val/Val Met/Met Val/Val Met/Met 
CT 321.4 ± 22.4 287.8 ± 23.1 148.9 ± 7.2 154.9 ± 5.9 31.8 ± 2.5   27.7 ± 1.2 
CFT 146.1 ± 13.6 105.3 ± 12.3* 43.4 ± 2.3 44.5 ± 3.3 72.8 ± 1.7 62.1 ± 0.8** 
MCF 55.9 ± 1.9 62.0 ± 0.8* 64.9 ± 1.1 68.0 ± 0.5* 60.7 ± 1.0 64.1 ± 1.9** 
MCE 130.1 ± 10.5 164.1 ± 5.6* 187.6 ± 8.1 212.9 ± 4.3* 156.0 ± 7.1 181.5 ± 6.8** 
Table 2 Thromboelastographic analysis. Test NATEM, INTEM and EXTEM on whole blood of Val/Val 
mice and Met/Met mice (n=10 mice per group). Data shown are ± SEM. * p<0.05, ** p< 0.01. 
 
3.1  Coagulation  factors  activity – To verify the results suggested by 
thromboelastographic analysis, related to normal activity of coagulation factors in 
Met/Met mice (similar CT in each test performed), we carried out a pro-coagulant 
activity test (PCA) in presence of factor deficient plasma to confirm this hypothesis. 
As expected, no alteration in the levels of each coagulation factor analyzed was 













































































































































Figure 3 Dosage of coagulation factors of intrinsic (FVIII, FIX, FXI, FXII), common (FV, FX, FII) and 
extrinsic (FVII) pathways of coagulation by PCA test in Val/Val (open bars) and Met/Met (black bars) 




In addition, we measured TF activity, main activator of coagulation cascade on 
thrombosis, in plasma microparticles, and in circulating leukocytes. The levels of 
microparticles TF activity were similar in Met/Met and Val/Val mice isolated from 
whole blood of Val/Val and Met/met mice, revealing only a trend of increasing in 
Met/Met mice than Val/Val (Figure 4A). Moreover, we observed that leukocytes, main 
carriers of circulating TF (Cermak, et al., 1993), isolated from Met/Met mice, coagulated 
faster than those isolated from Val/Val mice, meaning higher TF units (U TF/g 




































Figure 4 Dosage of Tissue Factor (TF) activity. A) microparticles TF activity (n=10 mice per group) and 
B) leukocytes TF activity (n=6-8 mice per group) in Val/Val (open bars) and Met/Met (black bars) mice. 
Data shown are ± SEM. 
 
3.2  Platelets  characterization – Since the shorter CFT obtained by 
thromboelastography in Met/Met mice associated with higher plasma levels of 
thrombospondin-1 (TSP-1), a protein released from -granules of platelets (Jurk, et al., 
2003), and increased serum thromboxane B2 (TXB2) levels in Met/Met mice than 
Val/Val mice (Figure 5A and B), suggest a hyperactive platelet phenotype, we next 














































Figure 5 Dosage of prothrombotic mediators. A) Plasma levels of Thrombospondin-1 and B) 
Thromboxane B2 serum release in Val/Val (open bars) and Met/Met (black bars) mice. (n=6 mice per 
group). Data shown are mean ± SEM. 
 
We firstly carried out the study of platelets aggregation in platelet rich plasma (PRP) 
obtained from Met/Met and Val/Val mice. A statistically significant difference in the 
threshold concentrations of collagen (0.0175 to 0.5 g/ml) and thrombin (from 0.0125 
to 0.05 U/ml) required to induce platelet aggregation was observed between the two 






































































Figure 6 Effect of collagen on platelets aggregation. Platelets aggregation induced by A) collagen 0.175 
g/ml, B) collagen 0.25 g/ml and C) collagen 0.5 g/ml in Val/Val (open circles) and Met/Met (black 
squares) mice (n=6 mice per group). Data shown are mean ± SEM. *p<0.05; **p<0.01; ***p<0.001. 
 
In particular, at the lowest concentration of collagen we observed only a modest 
difference between the two groups, but collagen 0.25 g/ml induced a strong Met/Met 
platelets aggregation (about 52%) already after 3 minutes of stimulation and reached a 
plateau (65%) at 5 minutes, whereas the maximal aggregation achieved by Val/Val 
platelets was only of 25% and of 44% at 3 and 5 minutes, respectively. In contrast, there 
were no differences in the aggregation induced by the highest concentration of collagen. 
Comparable results were obtained after activation of platelets with thrombin. Indeed if 
at the lowest concentration of thrombin we could not appreciate a relevant difference, 
after adding thrombin 0.025 U/ml Met/Met platelets reached an aggregation of 59% 
after 5 minutes while Val/Val platelets aggregated for only 41% (Figure 7A , B and C) 
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Figure 7 Effect of thrombin on platelets aggregation. Platelets aggregation induced by A) thrombin 
0.0125 U/ml, B) thrombin 0.025 U/ml and C) thrombin 0.05 U/ml in Val/Val (open circles) and Met/Met 
(black squares) mice (n=5 mice per group). Data shown are mean ± SEM. *p<0.05; **p<0.01 
 
To better characterize the hyperactivation of platelets observed in Met/Met mice, we 
evaluated by flow cytometry the expression of P-selectin, receptor involved in the 
interaction of platelets with leukocytes (Hu, et al., 2010), and of GPIIbIIIa, receptor 
designated to the binding of fibrinogen (Savage, et al., 1996), on washed platelets isolated 
from Met/Met and Val/Val mice in response to two concentrations of thrombin (0.01 
and 0.5 U/ml). P-selectin expression was higher in Met/Met mice than in Val/Val after 
the treatment with low concentration of thrombin (Figure 8A). The difference was lost 
when platelets were stimulated with thrombin 0.5 U/ml. On the other hand, receptor 
GPIIbIIIa expression was significantly increased in Met/Met mice for both thrombin 




















































Figure 8 Flow cytometry analysis: platelets receptors. A) P-selectin and B) GPIIbIIIa receptors 
expression induced by thrombin on Val/Val (open bars) and Met/Met (black bars) platelets (n=10 mice 
per group). Data shown are mean ± SEM. *p<0.05; ***p<0.001. 
 
The higher reactivity of Met/Met platelets was also indicated by the increased ability of 
platelets of binding fibrinogen after stimulation with Adenosine DiPhosphate (ADP 1 
M) (Figure 9). 
 



















Figure 9 Flow cytometry analysis: fibrinogen binding. Ability of Val/Val (open bars) and Met/Met (black 
bars) platelets to bind fibrinogen at baseline and after treatment with ADP (n=7-8 mice per group). Data 
shown are mean ± SEM. 
 
To determine the possible role of BDNF Val66Met polymorphism in outside-in 
signaling, we performed clot retraction assay, on PRP isolated from whole blood of 




difference between the two groups of animals, with a 35% reduction in the percentage 
of extruded serum, suggesting a defect in cytoskeleton dynamics (Egot, et al., 2013) 
(Figure 10 Ai and Aii). 
 























Figure 10 Clot retraction. Ai) PRP isolated from Val/Val (open circle) and Met/Met (black bars) mice 
was coagulated by the adding of thrombin and the time of retraction was measured, Aii) photographical 
representation of Val/Val and Met/Met clot retraction at 150 minutes (n=6 mice per group). Data shown 
are mean ± SEM. *p< 0.05; **p< 0.01. 
 
Key processes, induced by fibrinogen engagement, are cell spreading and activation of 
retractile signaling pathways. We therefore allowed platelets from Met/Met and Val/Val 
mice to adhere on fibrinogen coated-coverlips from 10 to 40 minutes under basal 
conditions. The number of adherent platelets on fibrinogen coated-surfaces was 
significantly increased in Met/Met mice (Figure 11A and B) compared to Val/Val mice. 
In particular, we observed that already after 20 minutes of incubation the number of 
platelets adhered on fibrinogen is 2 fold higher in Met/Met if compared to Val/Val mice 
















Figure 11 Platelets adhesion. Washed platelets of Val/Val (open bars) and Met/Met (black bars) mice let 
to adhere on fibrinogen coated-coverlips and then A) observed and B) counted by microscopy. Data 
shown are mean ± SEM of 6 independent experiments. *p< 0.05; ** p< 0.01. 
 
Finally we evaluated by flow cytometry the percentage of platelet-leukocyte aggregates 
on whole blood of Met/Met and Val/Val mice under basal and ADP (5 M) stimulated 
conditions. The percentage of platelet-leukocyte aggregates was significantly higher in 
Met/Met mice than controls in both conditions, in agreement with the data previously 











Figure 12 Flow cytometry analysis: number of platelet-leukocyte aggregates. Ai) Graphical 
representation and Aii) quantitation of platelet-leukocyte aggregates in Val/Val (open bars) and Met/Met 
(black bars) whole blood samples at baseline and after treatment with ADP; (n=8-9 mice per group). Data 
shown are mean ± SEM. *** p< 0.001. 
 
3.3  Contribute  of  fibrinogen - To determine the contribution of fibrinogen in 










































































test performed in whole blood samples and b) Clauss assay performed on plasma 
samples. 
From thromboelastometric FIBTEM assay was found that Met/Met mice have an 
increased MCF compared to Val/Val (Figure 13A). Similarly, the rate of fibrinogen to 
fibrin conversion detected by the conventional Clauss method resulted higher in 





































Figure 13 Functional fibrinogen. A) FIBTEM test (n=8 mice per group) by thromboelastography and B) 
Clauss test (n=11-10 mice per group) were performed on whole blood and PPP respectively of Val/Val 
(open bars) and Met/Met (black bars) mice to measure fibrinogen "biologically active". Data shown are 
mean ± SEM. 
 
Both these results support the hypothesis that the formation and polymerization of fibrin 
is more considerable in knock-in mutant mice. 
 
Finally, we measured some proteins involved in the clot stabilization and/or fibrinolytic 
processes. No differences were measured in terms of tissue plasminogen activator (tPA) 
activity, protein engaged also in pro-BDNF cleavage, and of plasminogen activator 
inhibitor type 1 (PAI-1) antigen and activity in plasma of Val/Val and Met/Met mice 
(Figure 14A and B). Remarkable, the tPA/PAI-1 antigen ratio was significantly lower 
(27%) in Met/Met mice compared to Val/Val mice, suggesting a hypo-fibrinolytic state 





























































Figure 14 Fibrinolytic proteins production and activity. A) tPA activity and Bi) PAI-1 production and 
Bii) activity in plasma of Val/Val (open bars) and Met/Met (black bars) mice (n=10 mice per group). Data 




4.1 Vessel wall proteomic analysis – Characterization of aorta tissue of Val/Val 
and Met/Met mice was here carried out. In particular, to determine the potential 
differences in aorta tissue protein in the two groups of animals, proteomic analysis of 
aorta secretome were performed. Aorta tissues of Val/Val and Met/Met mice were 
isolated, incubated for 24 hours in medium at 37°C and then supernatants were 
collected for characterizing the secretome. A total of 152 proteins were identified and 
quantified. 126 proteins were found in both genotypes, 8 were uniquely expressed in 
Val/Val mice and 18 uniquely in Met/Met mice (Figure 15A). The entire dataset was 
filtered by using only the identifications from LC-MSE data set with a good replication 






Figure 15 Proteomic analysis. A) Eulero-Venn diagram for identified proteins in the secretome of aorta 
from Val/Val and Met/Met mice to visualize proteins expressed uniquely in one of the two groups; B) 
Graphical representation of differentially expressed proteins between Val/Val and Met/Met mice 
identified by LC-MS
 E (n=10 mice per group). 
 
Table 3 shows the proteins identified by mass spectrometry, including those 
differentially expressed in two genotypes, those uniquely expressed from Val/Val or 
Met/Met mice, together with their fold changes (expressed as log (e) of the ratio 
between Val/Val and Met/Met mice), their variance and their probability. 
 
    val/val:met/met 
Accessio





Q9ERD7 Tubulin beta-3 chain  126.77 val /val       
P26443 Glutamate dehydrogenase 1, 
mitochondrial precursor  200.56 val /val 
Q7TMM9 Tubulin beta-2A chain  150.64 val /val 
P68372 Tubulin beta-2C chain 134.47 val /val 
P99024 Tubulin beta-5 chain  129.61 val /val 
Q922F4 Tubulin beta-6 chain  155.66 val /val 
O55023 Inositol monophosphatase  100.81 val /val 
Q9CWF2 Tubulin beta-2B chain 147.83 val /val       
P01869 Ig gamma-1 chain C region, membrane-
bound form  151.37  2.58 0.29 1 
Q9WVH9 Fibulin-5 precursor  392.73  0.4 0.1 1 
P37804 Transgelin  1037.0  0.3 0.04 1 
P58774 Tropomyosin beta chain  580.23  0.26 0.1 1 
P63268 Actin, gamma-enteric smooth muscle  669.34  0.24 0.05 1 








P62737 Actin, aortic smooth muscle  669.64  0.23 0.06 1 
P68134 Actin, alpha skeletal muscle 688.96  0.23 0.07 1 
P63260 Actin, cytoplasmic 2  791.89  0.22 0.06 1 
P13020 Gelsolin precursor  316.93  0.21 0.14 1 




7  0.21 0.04 1 
P21107 Tropomyosin alpha-3 chain  196.64  0.21 0.16 1 
Q9JJU8 SH3 domain-binding glutamic acid-rich-
like protein 276.41  0.19 0.18 0.98 
Q9WVA4 Transgelin-2  593.15  0.19 0.09 1 
P35700 Peroxiredoxin-1  192.1  0.19 0.16 0.98 
Q8BWT1 3-ketoacyl-CoA thiolase, mitochondrial 245.4  -0.25 0.18 0.02 
Q00897 Alpha-1-antitrypsin 1-4 precursor  291.7  -0.28 0.16 0 
P14152 Malate dehydrogenase, cytoplasmic 499.5  -0.28 0.09 0 
P01942 Hemoglobin subunit alpha  220.36  -0.29 0.11 0 
P07759 Serine protease inhibitor A3K precursor  845.63  -0.3 0.07 0 
P40142 Transketolase 739.13  -0.3 0.09 0 
Q03734 Serine protease inhibitor A3M precursor  565.16  -0.35 0.1 0 
Q61838 Alpha-2-macroglobulin precursor  733.74  -0.35 0.11 0 
P51174 Long-chain specific acyl-CoA 
dehydrogenase, mitochondrial precursor  436.97  -0.43 0.15 0 
P22599 Alpha-1-antitrypsin 1-2 precursor  278.33  -0.49 0.12 0 
P06801 NADP-dependent malic enzyme  504.28  -0.51 0.12 0 
Q00898 Alpha-1-antitrypsin 1-5 precursor  622.47  -0.52 0.1 0 
Q00896 Alpha-1-antitrypsin 1-3 precursor 172.36  -0.53 0.15 0 
P81105 Alpha-1-antitrypsin 1-6 precursor 171.73  -0.54 0.19 0 
P07758 Alpha-1-antitrypsin 1-1 precursor  172.36  -0.57 0.16 0 
P42125 3,2-trans-enoyl-CoA isomerase, 
mitochondrial precursor  301.79  -0.66 0.21 0 
P50396 Rab GDP dissociation inhibitor alpha  156.12 met/met 
P97807 Fumarate hydratase, mitochondrial 
precursor  150.75 met/met 
P20029 78 kDa glucose-regulated protein 
precursor  325.54 met/met 
Q91Z83 Myosin-7  708.41 met/met 
Q61598 Rab GDP dissociation inhibitor beta 316.08 met/met 




P68369 Tubulin alpha-1 chain  160.83 met/met 
Q01853 Transitional endoplasmic reticulum 
ATPase  337.1 met/met 
P68373 Tubulin alpha-6 chain  166.79 met/met 
P17182 Alpha-enolase  135.76 met/met 
Q9CR68 Ubiquinol-cytochrome c reductase iron-
sulfur subunit, mitochondrial precursor  117.84 met/met 
P97427 Dihydropyrimidinase-related protein 1  130.71 met/met 
P28665 Murinoglobulin-1 precursor  432.7 met/met 
P32261 Antithrombin-III precursor  219.84 met/met 
P13542 Myosin-8 741.74 met/met 
Q60597 2-oxoglutarate dehydrogenase E1 
component, mitochondrial precursor 301.08 met/met 
P13541 Myosin-3 672.17 met/met 
Q5SX39 Myosin-4  826.35 met/met       
Table 3 Secretome analysis. Differentially expressed proteins in the secretome of aorta specimens from 
Val/Val mice versus Met/Met mice identified by LC–MSE; (n=10 mice per group). 
 
Considering biological processes in which are involved the proteins identified, we could 
divide them in some main families: proteins componing cytoskeleton structures and 
regulating cell shape (i.e. tubulins, actins, lamins and transgelin), proteins important for 
cell motility (i.e. myosins, tropomyosins and vinculin), protein involved in 
inflammatory processes (i.e. alpha-1 antitrypsin) and proteins involved in the regulation 
of coagulation and fibrinolytic processes (i.e. gelsolin, serine-protease inhibitors, fibulin 
precursor and antithrombin III precursor). In particular, we studied the impact of 
Met/Met polymorphism on the expression of two proteins, alpha1-antitrypsin (A1AT), 
involved in inflammatory processes, and gelsolin, involved in coagulation/fibrinolytic 
events. In addition, we analyzed the tissue factor expression and activity also in aorta 
tissue. 
 
4.2 Inflammation pattern of Val/Val and Met/Met mice – The relevance of 
BDNF Val66Met polymorphism on inflammation, was then studied. Firstly, 1-
antitrypsin plasma levels were measured in the two groups of animals. Interestingly, 
A1AT was significantly higher in Met/Met mice than Val/Val mice (Figure 16A), 




erythrocyte sedimentation rate (ESR) as marker of chronic inflammation. ESR test 
measures how fast erythrocytes fall to the bottom of a tall, thin tube. Intriguingly, ESR 

















Figure 16 Plasma markers of inflammation state. A) 1-antitrypsin (n=8-10 mice per group) and B) 
erythrocytes sedimentation rate (ESR) (n=10 mice per group) were measured on plasma of Val/Val (open 
bars) and Met/Met (black bars) mice. Data shown are mean ± SEM. 
 
Both these results and the higher levels of leukocyte in peripheral blood, previously 
shown (Table 1), confirm the pro-inflammatory state of Met carriers mice than control 
mice. 
 
4.3  Gelsolin  and  Tissue  Factor  (TF)  in  Val/Val  and  Met/Met  mice – 
Proteomic analysis identified gelsolin as protein differentially expressed in aortas 
secretome from Val/Val and Met/Met mice. Gelsolin is involved in the actin remodeling 
(Osborn, et al., 2006) but also in the regulation of thrombus stability (Bohgaki, et al., 2011). 
Consequently we measured on plasma of Val/Val and Met/Met mice the levels of 
gelsolin: results showed that Met/Met mice plasma contains very lower amount of 





















Figure 17 Plasma gelsolin. Dosage of gelsolin was performed on plasma of Val/Val (open bar) and 
Met/Met (black bar) mice. (n= 6 mice per group). Data shown are mean ± SEM. 
 
In contrast, histological analysis (Figure 18A) and real time PCR (Figure 18B) showed 











Figure 18 Gelsolin expression in aorta tissue. Gelsolin expression was evaluated by A) histological 
analysis (immunoperoxidase staining) and B) real time PCR on aorta tissues of Val/Val (open bar) and 
Met/Met (black bar) mice; (n=12 mice per group). Data shown are mean ± SEM. 
 
Finally, we analyzed the expression and activity of Tissue Factor (TF) in vessel wall of 
the two groups of animals. Carotid arteries excised from Val/Val and Met/Met mice 
were lysed and processed for pro-coagulant activity (PCA) assay to measure TF activity 
while aortas were isolated and processed for real time PCR to measure TF mRNA 
expression. Vessel walls from Met/Met mice showed both higher activity (Figure 19A) 































































Figure 19 Tissue Factor activity and expression. TF A) activity and B) expression were measured in 
carotid artery (n=13 mice per group) or aorta tissues (n=8 mice per group) of Val/Val (open bars) and 
Met/Met (black bars) mice. Data shown are mean ± SEM. 
 
5  Effect  of BDNF Val66Met  polymorphism  on  serum  levels of 
BDNF 
To assess whether the pro-inflammatory and pro-thrombotic phenotype observed in 
Met/Met mice is the consequence of alteration in the systemic production of BDNF we 
measured BDNF serum levels in Val/Val and Met/Met mice. Despite we use two 
specific different BDNF detection kit, the circulating levels of this neurotrophin was 
very low (Kit R&D and Millipore Elisa Kit). However, the results obtained using the 
two different Elisa kit were very similar. Indeed, the serum levels of BNDF were 

























Figure 20 BDNF serum levels. Serum levels of Val/Val (open bars) and Met/Met (black bars) mice 
measured using A) R&D Elisa Kit and B) Millipore Elisa Kit (n= 6-8 mice per group). Data shown are 






In the last part of the study we performed some experiments to understand the real 
effect of the mutation Val66Met on “pro-thrombotic” phenotype observed in knock-in 
mutant mice. To reach this goal we transformed culture of HeLa cells with plasmids 
expressing the Val or Met sequence of proBDNF. By western blot analysis we 
visualized the correct transfection of HeLa cells, immunoblotted for C-terminal FLAG 
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Figure 21 Plasmids constructs transfection. Dual N-terminal HA (hemoagglutinin)-tagged and C-terminal 
FLAG-tagged proBDNF was transfected into HeLa cells, and after 24 hours were lysated as described in 
Materials and Methods and immunoblotted with anti-FLAG antibodies. 
Then we replicated some of the experiments carried out ex vivo, in particular, we 
analyzed levels of TF activity and gelsolin expression. 
TF activity was dosed by PCA assay (Figure 22A) and we observed that HeLa cells 
expressing Met mutation showed higher TF activity, that it is translated in higher levels 
of TF units (Figure 22A). Moreover, we demonstrated that gelsolin expression, detected 
by western blot analysis, was strongly induced in cells transformed with Met construct, 
compared to lipofectamine (controls) or with HeLa transformed with Val carrying-
plasmids, reaching values over 1.5 fold higher (Figure 22B). No difference in terms of 
gelsolin expression was detected between controls cells and cells transfected with 
plasmids expressing the Val sequence. 
These results suggest that the phenotype exacerbated in our mouse model may be a 
direct effect of the mutation BDNF Val66Met on peripheral compartment and not only a 
consequence of alterations in the central nervous system.  
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Figure 22 HeLA cells studies. HeLa cells were transformed with plasmids expressing Val (open bars) or 
Met (black bars) sequence; A) TF activity, Bi) Bar graphs summarize the changes in gelsolin protein 
content normalized to tubulin expression and Bii) representative images of western blot. Data shown are 
mean ± SEM of 6 independent experiments. 
Gelsolin 
Tubulin 

























4 DISCUSSION  
 
The relevant role of neurotrophins, in particular of brain derived neurotrophic factor 
(BDNF), in the cardiovascular system development (Hasan, 2013) and their involvement 
in cardiovascular risk (Caporali, et al., 2009) (Donovan, et al., 1995) (Lorgis, et al., 2009), suggest 
a potential role of these neuronal mediators, in cardiovascular disease, and specifically 
in thrombosis. 
In this study we provide evidence that genetic modification of BDNF gene, carrying the 
human single nucleotide polymorphism (SNP) Val66Met on the gene BDNF, 
exacerbates a prothrombotic and pro-inflammatory state. In particular, platelets, 
leukocytes and vessel wall show altered phenotype and functionality. 
 
We observed higher thrombogenicity in mice homozygous for Met allele compared to 
controls, in terms of mean time of occlusion, thrombus size and percentage of mortality 
after the induction of different thrombosis injury models, suggesting a critical role of 
BDNF Val66Met polymorphism in thrombotic events.  
These data may well concur with previous publications that showed that BDNF 
Val66Met polymorphism is independently associated with poor outcome at 2 weeks and 
at 1 year, and with worsening physical disability and cognitive function over that 
period, or with worsened surgical outcome in patients with unruptured brain 
arteriovenous malformation (Westbroek, et al., 2012), and that Met/Met genotype is 
involved in the pathogenesis of CAD in females and in the predisposition to CAD 
associated with depression (Bozzini, et al., 2009). Additionally, BDNF Val66Met 
polymorphism is associated with some cardiovascular risk factors, such as insulin 
resistance (Burghardt, et al., 2012) and metabolic syndrome (Zhang, et al., 2013), supporting 
our findings. However, a protective effect of BDNF Val66Met polymorphism on the 
occurrence of unstable angina pectoris (UAP) (Jiang, et al., 2009), or no correlation of this 
polymorphism with myocardial infarction (Stahelova, et al., 2011) were found. Several 
reasons can explain the different results obtained from these two studies. In particular, 
the different Caucasian/Asian phenotypes, in fact the genetic component of various 
CAD manifestations (MI and unstable angina) may partially differ. Caucasian and 




apparent in the frequency of investigated BDNF 66Met allele in Chinese controls (49%) 
(Jiang, et al., 2009) by comparison with Czech controls (17%). Furthermore, the 
differences in haplotype structure between both ethnicities may mask causal variants 
within the BDNF gene or nearby. In addition, the Czech study, despite involves well-
characterized group of MI patients, is disposed of lower statistical power to detect 
potential association of BDNF gene variant with CAD. The results of these studies 
should be viewed consequently with caution and need to be replicated in different 
population groups and settings, before a definitive relationship can be concluded upon. 
Moreover, the results need to be validated in a prospective study before adding this 
growing list of gene polymorphisms that are linked to CAD. 
Our results well support the hypothesis that BDNF Val66Met polymorphism affects the 
physiological hemostatic processes and lead to hypercoagulable state. In fact, 
thromboelastographic analysis shows that whole blood of Met/Met mice forms bigger 
and more stable clot compared to Val/Val mice and suggests increased platelets 
reactivity and functional fibrinogen alteration. 
In particular, higher platelet counts associated with a modest increase of reticulated 
platelets number were observed in Met/Met mice compared to controls. Platelets from 
Met/Met mice were more active as shown by higher levels of serum thromboxane B2 
(TXB2), enhanced clot retraction and aggregation, expression of membrane P-selectin 
and GPIIbIIIa as well as by greater ability to bind fibrinogen in response to multiple 
agonists. 
Higher platelets counts could be partially explain the higher thrombogenicity observed 
in Met/Met mice, in fact platelets number may contribute to the individual risk of 
thrombosis (de Gaetano, et al., 2010). 
In addition, reticulated platelets are more reactive platelets, aggregate more rapidly in 
response to collagen (Hirsh, et al., 1968), synthesize more TXA2 (Jakubowski, et al., 1983), and 
express more glycoprotein (GP)Ib and GPIIb/IIIa (Tschoepe, et al., 1990). Younger 
reticulated platelets are significantly increased in the blood of patients with acute 
coronary syndromes (ACS) (Huczek, et al., 2005) (Trowbridge, et al., 1984), in diabetic patients 
with vascular disease (Lakkis, et al., 2004) (Huczek, et al., 2005) (Brown, et al., 1997) and predict 
cardiovascular death (Lakkis, et al., 2004) (Cesari, et al., 2013). Of note, increased platelet 




al., 2012) and in people subjected to high levels of work stress (Camacho, et al., 2000), 
suggesting how depression and CVD are strongly linked. 
Activated Met/Met platelets adhere to leukocytes and form circulating mixed 
aggregates. The presence of increased circulating platelet-leukocytes aggregates has 
been observed in different cardiovascular diseases, such as stable and unstable angina, 
myocardial infarction and in patients undergoing percutaneous coronary interventions 
and heart valve replacement; additionally, platelet-leukocyte aggregates are a predictive 
index of acute re-occlusion following coronary angioplasty (Rezende, et al., 2013) (Buxhofer-
Ausch, et al., 2012) (Cerletti, et al., 2012) 
Again, the presence of platelet-leukocyte interaction is documented to be a link between 
inflammation, blood coagulation and vascular risk (Cerletti, et al., 2010), but also with 
depression. Indeed, Morel-Kopp et al. demonstrated that depression in addition to being 
associated with increased platelet activation and higher number of circulating CD62p 
(P-selectin) positive platelets, is also associated with more circulating platelet-leukocyte 
aggregates than controls (Morel-Kopp, et al., 2009). 
In fact, elevated circulating levels of platelet-leukocyte aggregates have been reported 
not only in cardiac patients but also in individuals of low socioeconomic status, a factor 
associated with chronic psychological stress (Camacho, et al., 2000). 
In our animal model increased platelet count is associated to higher leukocytes number 
in particular on neutrophil and monocyte populations and with pro-inflammatory 
markers as higher levels of 1-antitrypsin (A1AT), thrombospondin-1 (TSP-1), 
erythrocytes sedimentation rate (ESR) and “biologically active” fibrinogen (Gabay, et al., 
1999). These data underline the relation between platelets and inflammation (Santimone, et 
al., 2011) that in turn constitutes cardiovascular risk (Huang, et al., 2013). 
A1AT, an acute-phase reactant protein (Gettins, 2002) (Lockett, et al., 2013) plays a role in 
the local regulation of proteases involved in coagulation or fibrinolysis and represents a 
link between the inflammatory and hemostatic systems. 
A strong correlation between A1AT and thrombosis has been found (Moontfoort, et al., 
2013) and its plasma concentrations are increased in MDD patients (Maes, et al., 1992). In 
addition, BDNF Val66Met polymorphism resulted not only in a local increase 
expression of TSP-1 and its receptor CD36 in a post-stroke mouse model (Qin, et al., 




emerging role in platelet aggregation and thrombus adhesion to injured blood vessels 
and limits nitric-oxide-mediated vasodilatation and tissue perfusion in experimental 
models of ischemic injury (Isenberg, et al., 2007). In particular, higher plasma TSP-1 levels 
were measured in patients with coronary artery disease and diabetes mellitus (Kyu-Young, 
et al., 2012).  
Pavlovic et al. have demonstrated that ESR and higher fibrinogen concentration are 
correlated to metabolic syndrome in schizophrenic patients (Pavlovic, et al., 2013), 
producing another relationship among cardiovascular system, neurological disorders, 
inflammation and our mice model. All these findings are confirmed by several studies 
that propose a link between cardiovascular and depressive diseases with inflammation 
as common denominator (Karbach, et al., 2013) (Patas, et al., 2013). 
BDNF Val66Met mice showed alteration also in the coagulation and the fibrinolytic 
systems. Met/Met mice showed greater Tissue Factor (TF) activity in both leukocytes 
and aorta tissue, while the other coagulation factors of extrinsic, intrinsic and common 
pathway of the coagulation cascades were not altered. TF plays a central role in our 
carotid artery experimental model. Indeed, ferric chloride causes significant injury both 
to endothelium and to the arterial media, expecting the exposure of medial TF to the 
circulation. The relative contributions of arterial wall-bound versus circulating TF to 
thrombosis remain to be determined. It was shown that circulating TF is not sufficient to 
produce stable thrombi, but does not rule out the possibility that it contributes to 
thrombus propagation (Wang, et al., 2009), consistent with a recent report showing that TF 
is present in pathological thrombi but not in hemostatic plugs (Hoffman, et al., 2006). 
Concurring with this thesis, we showed that total microparticles (MPs) TF was not 
significantly changed in the two groups of animals. MPs release from endothelial cells 
and platelets occurs by regulated budding/blebbing of the plasma membrane and is 
induced upon subsequent increase of intracellular Ca2+ (Gyorgy, et al., 2011). Since the 
presence of BDNF Val66Met polymorphism affects vesicles sorting and release, 
process favored by intracellular Ca2+ flow, (Lu, et al., 2005), we speculate that the similar 
total TF antigen is linked to alteration in MPs formation. 
A strong but not significant decrease in the levels of tissue plasminogen activator (tPA) 
was detected in plasma isolated from Met/Met mice. In contrast the ratio between PAI-1 




inhibitor-1 (PAI-1) imbalance may play an important role in pathophysiology of mental 
and thromboembolic disorders. Indeed tPA facilitates clot dissolution and participates in 
several brain functions, including response to stress, learning and memory. Shi et al. 
showed reduction of plasma tPA and BDNF in late-onset geriatric depression patients 
(Shi, et al., 2010). On the other hand depression is characterized by high PAI-1 levels and 
is related to metabolic syndrome (Horisch-Clapauch, et al., 2013). 
Of interest, in our mouse model, plasma levels of gelsolin in Met/Met mice are lower 
than that of Val/Val mice; on the contrary, vessel wall gelsolin mRNA and protein 
expression are higher compared to controls. The difference in the expression levels of 
two isoforms, cytoplasmic and plasmatic, is explained by different roles exerted. Plasma 
gelsolin clear actin filaments from the blood circulation, acting as an extracellular-
scavenger system (EAAS) (Lind, et al., 1986). Cytoplasmic isoform plays roles in 
controlling several cellular processes such as phagocytosis (Arora, et al., 2004), motility 
(Kwiatkowski, 1999), apoptosis (Kwiatkowski, 1999), and platelet formation and activation 
(Casella, et al., 1981). The ability of plasma gelsolin to shorten actin filaments (F-actin) 
may therefore be of physiologic importance insofar as gelsolin-mediated diffusion of 
actin from the clot may restore the clot rheologic properties and makes it more sensitive 
to the lytic action of plasmin (Janmey, et al., 1992). In our mouse model, lower amounts of 
plasma gelsolin do not allow these processes, favoring the formation of a thrombus 
bigger and less prone to the lysis. Further investigations, in support of our observations, 
have demonstrated that F-actin can lead to platelet aggregation directly in vitro, and the 
presence of excessive F-actin in blood vessels, which can plug smaller vessels and 
decrease blood flow to promote the formation of blood clots, can be fatal (Vasconcellos, et 
al., 1993). In addition, gelsolin knockout mice (Gsn-/-) display impaired function of 
platelets, disruption of the organization of actin-based domains in osteoclasts, alteration 
in the formation of growth cones of neuritis and reduced migratory capacity of 
neutrophils during inflammation (Witke, et al., 1995). Among several diseases in which 
gelsolin is altered, such as cancer, infection or inflammation, amyloidosis, Alzheimer’s 
disease (Li, et al., 2012), there are also cardiovascular diseases. Indeed the expression of 
gelsolin in human heart tissues and mouse models is increased after different types of 




myocardial infarction (MI), and end-stage heart failure (Li, et al., 2009) (Yang, et al., 2000) 
(Mani, et al., 2008). 
Moreover, platelet gelsolin is highly expressed in patients with ACS (Liu, et al., 2012) and 
in rat after AMI (Liu, et al., 2013), and the increased levels of gelsolin in platelet reach 
plasma (PRP) are associated with the high platelet activation and increased level of F-
actin. Decreased plasma gelsolin concentrations have been detected in plasma from 
AMI patients and rats, indicating that EASS is suppressed in this pathological condition 
(Liu, et al., 2013) (Suhler, et al., 1997). Thus, it would seem that the genetic variant BDNF 
Val66Met polymorphism mimics a situation of cardiovascular damage. 
Finally, transfecting HeLa cells with the construct carrying or not the mutation 
Val66Met on BDNF gene, we reproduced some of the results obtained in animal model, 
supporting the hypothesis that the BDNF Val66Met mutation acts directly in peripheral 
cells and that what we observed in vivo could be due to a direct action of neurotrophin 
on the cardiovascular system and not only to a consequence of neuronal and innervation 
altered functionality. 
However, it remains to clarify if the pro-thrombotic and pro-inflammatory phenotype 
observed in BDNF Val66Met is closely tied to the alteration in the BDNF levels. The 
BDNF Val66Met polymorphism, characterized by incorrect vesicles folding of mature 
BDNF, leads to an impairment in its neuronal release and supposedly also affects 
peripheral release (Lee, et al., 2009). In fact, blood BDNF concentrations reflect brain-
tissue BDNF levels (Klein, et al., 2011). Studies performed on human expressing BDNF 
Val66Met polymorphism, showed that BDNF Val66Met homozygosity does not 
influence plasma BDNF levels in healthy human subjects (Luykx, et al., 2012), while there 
is a positive correlation between BDNF plasma levels and anxiety-like behaviors in Met 
carriers (Dalle Molle, et al., 2012). On the contrary, serum levels of BDNF in Met subjects, 
affected by mood disorders, are lower compared to controls, as demonstrated by several 
studies (Grande, et al., 2013) (Sotiropoulou, et al., 2013), thus suggesting effectively an altered 
platelets release. In fact, several studies have demonstrated that in human beings 
(Fujimura, et al., 2006) and in rat (Hochstrasser, et al., 2013) BDNF is stored and released in 
large quantities from platelets. However, the detection in plasma or serum of BDNF 




are undetectable in mouse blood (Klein, et al., 2011), while others measure both plasma 
and serum levels (Borrel-Pages, et al., 2006) (Okada, et al., 2012). 
Nevertheless, using two different Elisa kit, we observed a significant reduction of serum 
concentrations of BDNF in Met/Met mice compared to controls, suggesting that 
alteration on BDNF circulating levels might affect the pro-thrombotic phenotype in 
Met/Met mice. 
 
We demonstrated for the first time that the genetic variant BDNF (Val66Met) 
polymorphism exerts effect on thrombotic events, activating the hemostatic system and 
altering vessel wall anti-thrombotic and anti-inflammatory physiological nature. 
As previously discussed, the results here obtained are common for thrombosis, 
inflammation and depressive/neurological disorders. Thus, our study demonstrated that 
BDNF can be considered a link between cardiovascular and neurological health and 
pathology, activating also specific mediators of inflammation, constantly present in both 
cardiovascular and depressive disease. 
Most importantly, our study confirmed and further supported the emerging role and 







BDNF Val66Met mice, kindly given to us by the Laboratory of Francis S. Lee, Cornell 
Medicine University, were generated introducing the Val66Met mutation in an ApaI-
ApaI fragment containing the BDNF prodomain and put back into the targeting vector. 
A carboxyl terminal His tag was added by a PCR mutagenesis strategy to monitor 
protein expression. The loxP-Neo cassette was introduced into a EagI site as a positive 
selectable marker. A pGK-thymidine kinase cassette was used as a negative selectable 
marker. The targeting vector was comprised of a 1.5 kb short arm, a 4.8 kb long arm, a 
1.5 kb targeted sequence carrying the Val66Met mutation, and the Neo cassette flanked 
by two loxP sites. Linearized targeting vectors were electroporated into 129 mouse 
strain embryonic stem (ES) cells. DNA derived by G418/FIAU-resistant ES clones were 
screened using a diagnostic BglII + BamHI restriction enzyme digestion using the 5' 
probes external to the targeting vector sequence. Recombinant clones containing the 
predicted 7.4 kb rearranged band were obtained at a frequency of 1 in 40. Four positive 
ES clones were injected into C57BL/6 blastocysts, which were then introduced into 
pseudopregnant females. Chimeric animals were mated with C57BL/6 to produce 
heterozygous animals, and these mice were subsequently crossed with mice expressing 
Cre recombinase in germ cells to excise the neo cassette. BDNF Val/Val (WT) mice, 
heterozygotes and homozygotes mice for Met/Met mutation (BDNF Val/Met and 
BDNF Met/Met) were generated by interbreeding heterozygotes, and offspring were 
genotyped by PCR analysis of tail tip-derived genomic DNA, as described (Howe, et al., 
2005). All experiments were performed with 10-12 week-old animals. 
 
1.1 Arterial thrombosis model - FeCl3 injury of the carotid artery was performed 
as described (Mussoni, et al., 2001). Mice (gender matched) were anesthetised with 
ketamine chlorhydrate (75 mg/kg; Intervet) and medetomidine (1mg/kg; Virbac). The 
left carotid artery was dissected free. Carotid blood flow was monitored by means of a 
Doppler flow probe (model 0.7V, Transonic System) connected to a transonic flow 




minutes at least 0.8 mL/sec), a 1x1 mm strip of filter paper (Whatman N°1) soaked with 
FeCl3 (20% solution; Sigma-Aldrich) was placed over the carotid artery. After 3 
minutes the filter paper was removed, the carotid artery was washed with phosphate-
buffered saline (PBS), and the flow was recorded. An occlusion was considered to be 
total and stable when the flow was reduced by >90% of baseline within and during 5 
minutes, where the flow during that 5-minute period did not change by more than 1% of 
baseline per second. 
 
1.1.1 Histological  analysis - Mouse carotid arteries were excised, gently perfused 
with PBS and fixed in 10% neutral formalin, processed, and then embedded in paraffin. 
Sections (5 m) were mounted on SuperFrost® Plus microscope Slides (VWR 
International), and thrombi were visualized with hematoxylin and eosin (H&E) staining. 
 
1.2 Platelet pulmonary thromboembolism - Collagen plus epinephrine-induced 
pulmonary thromboembolism was carried out in Met/Met and Val/Val mice. Mice were 
challenged with 0.1 ml of a mixture containing 480 µg/Kg collagen (MasciaBrunelli, 
Milan, Italy) and 60 M/Kg epinephrine (Sigma-Aldrich), rapidly injected into one of 
the tail veins. The mortality of mice in each group was monitored over 15 minutes and 
data are presented as percentage of animals dead over total number of animals tested. At 




Blood samples were collected by cardiac venipuncture from anesthesized (ketamine 
chlorhydrate 75 mg/Kg/medetomidine 1 mg/Kg in physiologic water) Val/Val and 
Met/Met mice (gender-matched), into 3.8% sodium citrate (1 parts sodium citrate/ 9 
blood). 
 
2.1 Platelets  rich plasma  (PRP) and platelets poor plasma  (PPP) – Blood 
samples, collected as previously described, were diluted 1:1 with Hepes-Tyrode’s buffer 




MgCl2, 2.7 mM KCl, 3.3 mM NaH2PO4) and centrifuged at 100g for 10 minutes. 
Platelet rich plasma (PRP) was gently removed with a plastic pipette and platelet counts 
were carried out in a Burker chamber after 1:200 dilution of the sample into Hepes 
Tyrode’s buffer. Platelet-poor plasma (PPP) was obtained by centrifugation of the 
remaining blood at 2000 g for 20 minutes. 
 
2.2  Serum  isolation – Blood samples, collected by orbital sinus bleeding, were 
maintained at 37°C for 2 hours, then transferred in ice for 30 minutes. Serum was 
obtained by a centrifugation at 2000 g for 20 minutes. 
 
2.3 Platelets, red blood cells and white cells counts in whole blood - Blood 
from gender-matched mice was collected by orbital sinus bleeding into Unopette 
pipettes and immediately diluted in Unopette®-System reservoirs (Becton Dickinson) 
containing 1% ammonium oxalate. After thorough mixing, platelets, red blood cells and 
leukocytes were counted optically, using the Brecher-Cronkite method, by an operator 
blinded to the experimental groups. 
 
2.3.1  White  cell  populations  count - Neutrophil granulocytes, monocytes and 




3.1  The  thromboelastography - The technology of ROTEM® is based on 
measurement of the viscoelastic changes that happening during coagulation in vitro. 
Thus, this technique is providing a unique possibility to evaluate initialization, 
formation and stability of the clot strength. 
A whole blood citrated sample, isolated as previously described, is incubated in a heated 
cup at 37°C. Within the cup is suspended a pin connected to a detector system, that is an 
optical detector. The cup and pin are oscillated relative to each other through an angle of 
4°75’. The movement is initiated from either the cup and the pin. As fibrin forms 




at the pin and a trace generated (Luddington, 2005). An analogic converter is able to 
translate the electromechanical signal into a signal converted by a specific software (Di 
Benedetto, et al., 2003). Different tests have been performed. 
 
Recalcification time test (NATEM): To perform the test 7 µl of reagent containing 
CaCl2 (STARTEM) 200 mM have been added to blood sample (105 µl). 
 
Test for evaluating extrinsic pathway of coagulation (EXTEM): In this test the 
coagulation is triggered by a small quantity of thromboplastin (Tissue Factor-TF). To 
perform the test 7 µl of reagent containing thromboplastin derived from rabbit brain 
(EXTEM) and 7 µl of STARTEM 200 mM have been added to 105 µl of blood sample. 
 
Test for evaluating intrinsic pathway of coagulation (INTEM): In this test the 
activation of contact phase is permitted by a high negative charge surface that is formed 
by the adding of ellagic acid and phospholipids. To carry out the test 7 µl of reagent 
containing ellagic acid and phospholipids (INTEM) and 7 µl of STARTEM 200mM 
have been added to 105 µl of blood sample. 
 
Test for evaluating the contribute of fibrinogen to the coagulation (FIBTEM): In this 
test the coagulation is activated by TF and it is influenced by adding of cytochalasin D 
that is an inhibitor of cytoskeleton of all cells. In this way platelets contribute is 
excluded since it is inhibited their shape change and consequently their activation. To 
perform the test 7 µl of FIBTEM (reagent containing cytochalasin D) and 7 µl of 
STARTEM 200 mM have been added to 105 µl of blood sample. 
 
Parameters measured: CT (Clotting Time): it is the necessary time for the formation of 
a clot with a diameter of 2 mm, from the beginning of the test and the addition of 
coagulation activator. CT is then the time in which thrombin is generated and the 
polymerization of fibrin begins. It is measured in seconds and it is visualized as a linear 
trace. CT is a useful parameter in the active state of the coagulation factors involved in 
the formation of thrombin, in both intrinsic and extrinsic pathway (depending on the 




CFT (Clot Formation Time): this parameter describes the kinetic of a stable clot 
formation by activated platelets and fibrin. It is the time between a clot of 2 mm to one 
of 20 mm. CFT is a measure of the necessary velocity to reach a specific level of 
strength of the clot and it is influenced by the number and the functionality of platelets, 
moreover also fibrinogen and the capacity of polymerization influenced this parameter. 
MCF (Maximum Clot Firmness): it is a measure of the consistence of the clot. It is 
represented as the maximum amplitude obtained before that fibrinolysis reduces the clot 
consistence. It is expressed in mm. As MCF indicates the increasing stability of the clot 
by the complete polymerization of the fibrin, all cellular components (not only platelets 
but also erythrocytes and leukocytes) and FXIII influence this parameter. 
MCE (Maximum Clot Elasticity): it is a measure of the elasticity of the clot. It is a 
parameter derived from MCF and it is expressed in mm. More MCE is higher more the 
clot is stable to the rupture. 
 
3.2  Dosage  of  coagulation  factors – Plasma samples, obtained as previously 
described, were coagulated in presence of coagulation factor deficient plasma, 
depending on coagulation factor analyzed. To 100 l of tested plasma, diluted 1:10 or 
1:20 in imidazole buffer (Hyphen Biomed), was added 100 l of deficient factor 
plasma. After incubation of 1 minute at 37°C, TF (EXTEM, ROTEM®) and CaCl2 
(STARTEM, ROTEM®) were introduced and recalcification time was recorded. 
Recalcification time, monitored from the adding of CaCl2 until the formation of fibrin 
clot, is determined in plastic cuvettes by manual fuss, in temperature bath at 37°C. 
Percentage of coagulation factor was found interpolating the clotting time on a standard 
curve at known concentration. 
 
3.3 Measurement of Tissue Factor activity – Samples preparation. Leukocytes: 
leukocytes were isolated from whole blood collected as previously described, and 
subsequently diluted 1:2 with Tyrode Buffer. PRP was obtained as described in chapter 
2 materials and methods, discarded, and the remaining fraction was diluted 1:20 with 
buffer for leukocytes (NH4Cl 155 mM, KHCO3 10 mM, EDTA 0.1mM), and hold in ice 
for 30 minutes. Following it was centrifuged at 650 g at 4°C for 10 minutes, washed 




obtained was dissolved in 150 µl of β-octil 15 mM. Later, for PCA assay, samples were 
sonicated for 30 seconds and hold at 37°C for 15 minutes. Carotid artery: carotid artery 
excised from Val/Val and Met/Met mice were cut, resuspended in 150 µl of β-octil 15 
mM, sonicated for 30 minutes and hold at 37°C for 15 minutes before performing PCA 
assay. After specific protein quantification (Bradford method) samples were 
conveniently diluted with HEPES to obtain final protein concentration of 4 µg/40 μl and 
1.25 µg/40 μl for leukocytes and carotid artery, respectively. HeLa cells: cells, after 
stimulation, were washed in PBS and lysed in 150 l/well of β-octil 15mM at 37°C. 
Adherent cells were pull out with scraper and then diluted in 300 l of HEPES 25 mM. 
 
Pro Coagulant Activity (PCA) assay. Procoagulant activity was measured by 
recalcification time test of citrated mouse plasma pool at 37°C. To 40 µl of sample, pre-
incubated at 37°C in temperature bath for 1 minute, were added 40 µl of PPP and 40 µl 
of CaCl2 15 mM. Recalcification time, monitored from the adding of CaCl2 until the 
formation of fibrin clot, is determined in plastic cuvettes by manual fuss, in temperature 
bath at 37°C. Recalcification times have been converted in arbitrary units of tissue 
factor (TF) by using a calibration curve of thromboplastin extracted from human 
placenta (Behring). 
 
3.4 Functional Fibrinogen (Clauss Method) – Blood collected, was centrifuged 
to obtain PPP, as previously described. PPP was then stored at -20°C till its analysis. 
Dosage of fibrinogen was performed by Clauss method adding to diluted sample high 
concentration of thrombin (100 U/ml, Sigma-Aldrich), as the clot formation is directly 





4.1 Platelet aggregation and adhesion - Platelet aggregation. Blood, isolated as 
previously described, was processed to obtain PRP. Platelet counts were adjusted to 250 




turbidimetric technique (Elvi Logos aggregometer) and was initiated by addition of 
various concentrations of collagen (0.175-0.5 µg/ml) or thrombin (0.0125-0.050 U/ml) 
and tracings were recorded for 5 minutes. 
 
For platelets adhesion, coverlips (10 mm Ø) were coated with 0.1 mg/ml fibrinogen 
overnight, followed by blocking with 2% BSA for 1 hour. Washed platelets (WPs) were 
obtained by serial centrifugations of PRP with addition of 0.2 µM PGI2 and 0.01 mg/L 
apyrase. Two-hundred l containing 6 x 106 platelets were added to fibrinogen-coated 
coverlips and platelets allowed to adhere for the indicated time at 37°C. Wells were 
washed with PBS to remove non-adherent platelets, while adherent platelets were fixed 
with 4% paraformaldehyde for 10 minutes, permeabilized in 0.2% Triton X-100 for 5 
minutes, washed with PBS, blocked with 3% BSA for 1 hour and stained with 
Alexafluor 488-phalloidin (1:200, Invitrogen) for 1 hour at room temperature. 
 
4.2 Flow cytometry analysis – Flow cytometry was performed on a FACS Calibur 
Instrument (BD Bioscience), using CellQuest version 3.1 software (BD Bioscience), 
collecting 3000 events per sample. 
 
Platelets size measurement. WPs were obtained by serial centrifugations of PRP with 
addition of 0.2 µM PGI2 and 0.01 mg/L apyrase. Platelets were identified by forward 
and side scatter distribution, and by anti-CD41 (BD Biosciences) positivity. 
 
Reticulated platelets. Reticulated platelets (RP) were identified by the thiazole orange 
method (Rocca, et al., 2002): 10 l of PRP were incubated with 390 l of thiazole orange 
(Retic-Counted, BD Bioscience) or PBS as control and anti-CD41 at room temperature 
for 10 minutes, in the dark, immediately after incubation, samples were analyzed by 
flow cytometry collecting 10,000 CD41-positive events; the percentage of RP recorded, 
and the absolute number of RP was calculated by multiplying by the platelet count. 
 
Platelets-fibrinogen binding ability, GPIIbIIIa and P-selectin expression. WPs were 
obtained by serial centrifugations of PRP with addition of 0.2 µM PGI2 and 0.01 mg/L 




concentration of 250 x 103 platelets/µl. Platelet activation was assessed by binding to 
AlexaFluor488-labeled fibrinogen (Invitrogen, Life Science/Biotechnology, Carlsbad, 
CA) using a PE-conjugated JON/A (Emfret Analytics, Elbestadt, Germany) antibody, 
raised against GPIIbIIIa (IIIII integrin) and with anti-CD62P, FITC-conjugated 
antibody (P-selectin, BD Bioscience, San Jose, CA). Twenty-five L of WPs (5x104/uL 
in Hepes-Tyrodes buffer supplemented with 1 mM CaCl2 and 0.35% BSA) were mixed 
with a saturating concentration of antibody and the mixture reacted with different 
concentrations of  thrombin for 15 minutes at room temperature. The reaction was 
stopped by 400 µL ice-cold PBS, and samples were analyzed within 30 minutes. 
 
Platelets-leukocytes aggregates.  Citrated blood from Val/Val and Met/Met mice was 
stimulated with ADP (5 μM, Sigma-Aldrich, Italy) for 5 minute and fixed with BD lysis 
buffer; samples were stained with the antibodies anti-CD45 and anti-CD42c and 
analyzed. 
 
4.3 Clot retraction on PRP – PRP obtained as previously described, was clotted in 
presence of 1 l of autologous whole blood, recalcified with 2 mM CaCl2, by adding 5 
U/ml of bovine thrombin (Sigma-Aldrich). Samples were incubated at 37°C and clot 
retraction was recorded photographically over 150 minutes. 
 
5 Prostanoids and plasma/serum biomarkers 
TXB2, stable metabolite of TXA2, was measured in sera of Val/Val and Met/Met mice, 
by Thromboxane B2 EIA kit (Cayman Chemical, Ann Arbor, MI). 
Plasma and serum biomarkers were quantified by specific commercial ELISA kits. tPA 
activity: ELISA Kit for Plasminogen Activator, Tissue (tPA) (Uscn, Life Science Inc., 
Wuhan, Hubei, China); PAI-1 activity: Murine PAI-1 activity assay (Molecular 
Innovation, Inc., Novi, MI); PAI-1 antigen: Mouse PAI-1 total antigen assay ELISA kit 
(Molecular Innovation, Inc., Novi, MI); Thrombospondin-1: ELISA Kit for 
Thrombospondin 1 (THBS1) (Uscn, Life Science Inc., Wuhan, Hubei, China); 1-
antrypsin: ELISA Kit for Alpha-1-Antitrypsin (1AT) (Uscn, Life Science Inc., Wuhan, 




ELISA Kit for Gelsolin (GS) (Uscn, Life Science Inc., Wuhan, Hubei, China). BDNF: 
human BDNF Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, U.S.A.) and 
ChemiKine TM Brain Derived Neurotrophic Factor (BDNF) Sandwich ELISA kit 
(Millipore, Billerica, MA, U.S.A.). 
 
6 Erythrocytes Sedimentation Rate (ESR) 
Blood samples were collected by orbital sinus bleeding in heparinized micro 
haematocrit tubes. Samples were immediately put vertically in plastic cuvettes and after 
2 hours was measured the ratio between plasma and erythrocytes sediment. The results 




7.1  Aorta  secretome  analysis - Sample preparation. Aorta rings were rinsed 
thoroughly with cold phosphate-buffered saline to remove any blood components and 
then were incubated in medium 199 without phenol red at 37°C for 24 hours (1 ml 
medium for 100 mg tissue). Conditioned media were collected, centrifuged for 5 
minutes at 1000 g at 4°C to remove cell debris, and the clear supernatant was dialysed at 
4°C using a 3500 molecular weight cut-off dialysis tube (Spectrum Laboratories, 
Rancho Dominguez, CA, USA) against 5 L of 1 mmol/L NH4HCO3 with two buffer 
exchanges at 4°C for 4 h, followed by dialysis against 0.75 mmol/L NH4HCO3 for 4 
hours, 0.5 mmol/L NH4HCO3 for 16 h, 0.25 mmol/L NH4HCO3 for 4 hours, and a last 
step against distilled water for 4 hours. The samples were then concentrated by means 
of lyophilisation and stored at -80°C. 
 
Preparation of protein digest. After lyophilisation, the secreted protein pellets were 
dissolved in 25 mmol/L NH4HCO3 containing 0.1% RapiGest (Waters Corporation, 
Milford, MA,USA), sonicated and centrifuged at 13000 g for 10 minutes. The 
supernatants were collected and the protein concentrations determined using Bradford’s 
method: 45 µg of each sample were heated at 80°C for 15 minutes, reduced with 5 




iodacetamide for 30 minutes at room temperature. Digestion was performed using 1 µg 
of sequencing grade trypsin (Promega, Milan, Italy) overnight at 37°C. After digestion, 
2% TFA was added to hydrolyse RapiGest and inactivate trypsin, and the solution was 
incubated at 37°C for 20 minutes before being vortexed and centrifuged at 13000 g for 
10 minutes. 
 
LC-MS analysis. Nanoscale LC separations of tryptic peptides for qualitative and 
quantitative multiplexed LC-MSE analysis were performed using a nanoACQUITY 
system. Aortas excised from Val/Val and Met/Met mice (0.4 μg) were mixed with 50 
fmol yeast alcohol dehydrogenase (ADH) digest as an internal standard for molar 
amount estimation (Silva, et al., 2006), and injected into a 180 μm × 2 cm Symmetry C18 (5 
μm) trap column (Waters Corporation, Milford, MA, USA) for preconcentration and 
desalting. The peptide mixtures were subsequently directed from the pre-column to a 
1.7 μm BEH 75 μm × 250 mm analytical column (Waters Corporation, Milford, MA, 
USA). The samples were eluted at a flow rate of 300 nL/minutes by increasing the 
organic solvent concentration from 1% to 40% B over 90 minutes, using 0.1% formic 
acid in water as reversed phase solvent A, and 0.1% formic acid in acetonitrile as 
reversed phase solvent B. All of the analyses were made in triplicate. 
The precursor ion masses and associated fragment ion spectra of the tryptic peptides 
were measured using a SYNAPT-MS, a hybrid quadruple orthogonal acceleration time-
of-flight Q-Tof mass spectrometer (Waters Corporation, Milford, MA, USA) directly 
coupled to the chromatographic system. The time-of-flight analyser of the mass 
spectrometer was externally calibrated using NaI from m/z 50 to 1990, and the data 
post-acquisition lock mass data was corrected using the monoisotopic mass of the 
doubly charged precursor of [Glu1]-fibrinopeptide B (m/z 785.8426) delivered to the 
mass spectrometer at 100 fmol/μL through a NanoLockSpray interface using the 
auxiliary pump of a nanoACQUITY system at a flow rate of 100 nL/minutes. The 
reference sprayer was sampled every 30 seconds. Accurate mass data were collected in 
DIA by alternating low and high energy applied to the collision cell. The spectral 
acquisition time in each mode was 0.6 seconds, with a 0.1 seconds inter-scan delay. In 
the low energy MS mode, data were collected at constant collision energy of 3 eV; in 




seconds scan. The RF applied to the quadruple mass analyzer was adjusted in such a 
way that ions from m/z 300 to 2000 were efficiently transmitted, thus ensuring that any 
ion with a mass of less than m/z 300 only arose from dissociations in the collision cell. 
 
Data processing and protein identification. The DIA data were processed and searched 
using ProteinLynx GlobalSERVER (PLGS) version 2.3 (Waters Corporation, Milford, 
MA, USA). Ion detection, data clustering, and the normalisation of the data-independent 
LC-MSE data has been previously explained in detail (Geromanos, et al., 2009) (Li, et al., 
2009). The proteins were identified by searching a human species-specific UniProt 
database (release 57.0; 20333 entries). The principle of the search algorithm has been 
recently described (Li, et al., 2009). The following search criteria were used for protein 
identification: the default search parameters included the “automatic” setting for mass 
accuracy (approximately 10 ppm for precursor ions and 25 ppm for product ions); a 
minimum of one peptide match per protein, a minimum of three consecutive product ion 
matches per peptide, and a minimum of seven total product ion matches per protein; up 
to one missed cleavage site allowed; carbamidomethyl-cysteine as fixed modification; 
and methionine oxidation as variable modification. The initial protein false-positive rate 
(FPR) of the identification algorithm was set at 4% using a randomised database that 
was five times larger than original database, leading to a peptide FPR that was typically 
smaller than 1%. However, using replication as a filter, the false-positive rate of the 
experiment is minimised because false-positive identifications have a random nature 
and do not tend to replicate across injections. 
The absolute quantity of each well-characterised protein in the mixture was determined 
by dividing the average MS signal response of the three most abundant tryptic peptides 
of each protein by the signal response factor as previously described (Silva, et al., 2006). 
The quantitative analyses were made using the ExpressionE algorithm in PLGS 2.3 by 
comparing the normalised peak area/intensity of each peptide in a control and a 
challenged sample. The data set was automatically normalised. Briefly, in the case of 
complex samples, it is often possible to measure and correct for systematic errors by 
taking into account slight differences in protein loading amounts without using an 
internal standard. The assumption is that changes in protein expression occur against a 




peptide or cluster is initially treated as an internal standard by the quantification 
algorithm and, during this step, the peptides showing real changes are naturally 
suppressed as occurs in the case of inappropriate assignments or interferences in normal 
quantification. Subsequently, the entire data set is corrected and quantified. 
Quantification has been done quantifying the peptides identified with the protein, and 
regulation likelihood was calculated using confidence of identification at peptide level 
as a quantification weighting mechanism, a method specifically designed for 
independently acquired LC-MS data. The overall likelihood of regulation, determined 
using the Quantify algorithm within PLGS 2.3 based on Bayesian statistics, is expressed 
by the probability of up-regulation: if this is <0.05 (i.e. between 0 and 0.05), the 
likelihood of down-regulation is >95%; if it is >0.95 (i.e., between 0.95 and 1) the 
likelihood of up-regulation is >95%. 
The entire data set of differentially expressed proteins was further filtered by 
considering only the identifications from data with identified peptides that replicated at 
least two out of three technical instrument replicates. Furthermore, the significance of 
the regulation level was determined at 20% fold change, which is typically 2-3 times 
higher than the estimated error in intensity measurement (Vissers, et al., 2007). 
 
7.2  Aorta  immunohistochemistry - Immunohistochemistry analysis was 
performed on sections of aortas of Val/Val and Met/Met mice. Samples were fixed 
overnight in 4% formalin, dehydrated in a scale of alcohols and embedded in paraffin. 
All samples were cut in sections of 3 m and mounted on polarized slides. Slides were 
rehydrated, washed in PBS containing 1% Triton X100 and treated with 3% H2O2 
(Sigma Life Science) for 10 minutes to block endogenous peroxidase. Antigen retrieval 
was performed with 0.01 M citrate buffer (pH 6) in a water bath at 95°C for 10 or 30 
minutes according to the antibody used. Slides were incubated overnight at 4°C with the 
following primary antibodies: anti-gelsolin polyclonal antibody (1:300, Novus 
Biologicals) or with rabbit pre-immune IgGs or goat pre-immune IgGs (Vector 
Laboratories, Burlingame, CA) as negative controls. After incubation with primary 
antibodies, sections were incubated with secondary antibodies: polyclonal anti-rabbit 
secondary antibody biotinylated (Dako cod. E0432) or anti-goat secondary antibody 




was developed using 3,3-diaminobenzidine (Dako cod.K3468) as chromogen and all 
sections were lightly counterstained with hematoxylin. Observation and digitalization 
was performed by a Zeiss Axioskop (Carl Zeiss) equipped with an intensified charge-




8.1 Cell culture – Human malignant epithelial cells (HeLa) were cultured in sterile 
flasks and maintained in DMEM + GlutaMAX medium (Invitrogen) supplemented with 
HEPES (1mM, Invitrogen), 100 U/mL penicillin (Gibco), 100 μg/mL streptomycin 
(Gibco) and 10% FBS, at 37°C in 5% CO2/95% air atmosphere. Almost every 3 days 
they were moved away with trypsin (trypsin/EDTA) and transferred in new flasks after 
1:4 dilution. 
For transformation experiment, cells were dished on multiwell plates in DMEM + 
GlutaMAX medium supplement with HEPES (1mM) and FBS 10% without antibiotics. 
After reaching confluence of 90-95% cells were transformed with Val or Met plasmids. 
 
8.2 Plasmids constructs – Plasmid construct were prepared as previously described 
(Chen, et al., 2004). Briefly, The human BDNF cDNA were subcloned into 
pCDNA3.1hygro expression vector (Invitrogen, Carlsbad, CA) using HindIII and XhoI 
sites. The HA or Flag epitope tag was added to the 3’ and 5’ respectively of the BDNF 
cDNA by PCR method. The Val to Met mutation at position 66 was generated by means 
of two-step PCR. Using PCR-based mutagenesis, a silent NotI site was generated 
immediately after the signal peptide of human BDNF to facilitate generating dual-
epitope-tagged HA-BDNF-Flag construct. The HA tag was inserted just before signal 
peptide of human BDNF and the Flag tag was attached to C-terminal of BDNF. 
 
8.3  Plasmids  isolation,  amplification,  purification  and  transfection – 
Transformation of Escherichia Coli. E. coli (grown in LB Broth medium bacteria) 




suspension) expressing WT or mutated sequence for BDNF (3.1 hygro HA-Val/Met-
Flag) (supplied by Chen’s group). 
 
Isolation of plasmid DNA. DNA was isolated and purified by Zyppy Plasmid Miniprep 
Kit (ZYMO RESEARCH Corporation, Irvine, CA). 
 
Plasmid bacterial amplification. After verifying the presence and purity of plasmids, 
bacterial cells expressing Val or Met construct were let to grow o/n (100 l of bacteria 
in 300 l of LB Broth base medium). 
 
Purification of plasmids. EndoFree Plasmid Maxi Purification kit (QIAGEN, Hilden, 
D) was used for purification of plasmids. 
 
HeLa Transfection. Fresh DMEM + GlutaMAX medium supplemented with HEPES 
(1mM), 10% FBS without antibiotics was added to cells at confluence of 90-95% and 
plasmids transfection was performed. Val or Met plasmids (4 g/l per well) were 
transfected in cells by lipofectamine 2000 (10 L/well Invitrogen) and incubated for 7 
hours with cells. The following day medium was changed with DMEM + GlutaMAX 
medium supplemented with HEPES (1mM), 10% FBS and antibiotics. After o/n 
incubation, cells were collected in RIPA buffer for western blot analysis or processed 
for PCA analysis. 
Occurred transfection of plasmids was verified with western blot analysis incubating 
cell lysates with polyclonal Flag antibody (Sigma-Aldrich) that can detect both pro- and 
mature BDNF. 
 
8.4 Protein preparation and  immunoblotting - HeLa cells were lysed in cold 
RIPA buffer (25 mM TRIS HCl, 100 mM NaCl, 2.5 mM EDTA, 1% Triton-X-100, 
0.1% SDS, 1 mM Na3VO4, 1 mM PMSF, 10 mM Na-pyrophosphate, 10 mM NaF pH 
8.0 and protease inhibitor cocktail) and protein yield was quantified using the BCA 
protein assay kit (Sigma Aldrich). Thirty µg samples were prepared with the Laemmli 
method, and equivalent amounts of protein were separated on 7% SDS-PAGE gels, 




anti-FLAG (1:5000, Sigma Aldrich), anti-gelsolin (1:1000, Novus Biological),and anti-
tubulin (1:10000; Sigma Aldrich) as a loading control. Subsequently membranes were 
incubated with peroxidase-conjugated secondary antibody, and immunoreactive bands 
were visualized by enhanced chemiluminescence (Thermo Scientific, Rockford, IL). 
 
9 Real time PCR (RT‐PCR) 
Total cellular RNA was isolated from cells or aorta tissue with TRIzol Reagent 
according to the manufacturer’s instructions. 1µg of RNA was reverse transcribed using 
SuperScriptTM II RNase H (Invitrogen). qRT-PCR was then carried out to assay TF, 
gelsolin and GAPDH was used for normalization. The primers used were: 
1. Mouse TF: forward 5’-CGGGTGCAGGCATTCCAGAG -3’, reverse 5’- 
CTCCGTGGGACAGAGAGGAC-3’;  
2. Mouse Gelsolin : forward 5’-AGATCTGGCGTGTGGAGAAG -3’, reverse 5’- 
CACAGTAAAGATGGCAGCAG-3’;  
3. Mouse GAPDH: forward 5’- CGTGCCGCCTGGAGAAACC-3’, reverse 5’- 
TGGAAGAGTGGGAGTTGCTGTTG -3’. 
Samples of cDNA (2.5 µl) were incubated in 25 µL IQ Supermix containing TF, 
Gelsolin or GADPH primers and fluorescent dye SYBR Green (Bio-Rad Laboratories). 
qRT-PCR was carried out in triplicate for each sample on the CFX Connect (Bio-Rad 
Laboratories). Gene expression was analyzed using default and variable parameters 
available in the software suite provided with the CFX Connect real-time PCR Detection 
System (Bio-Rad). The PCR threshold cycle number (CT) and starting quantity of test 
RNA samples were calculated after PCR baseline subtraction and CT determination had 
been carried out on the standards. Standard curve equations were calculated by 
regression analysis of the log of the copy number (starting quantity) versus threshold 
cycle. The standard curve equations (R2 usually >0.96) were used to calculate quantities 
of test RNA. The mean relative fluorescence units were calculated using individual well 
readings within a given PCR run on biological samples and then converted to mean fold 
change comparing mean relative fluorescence units of control samples versus mean 





10 Statistics - Statistical analyses were performed using GraphPad Prism 4 software. 
Data were analyzed by Student’s t test or by 2-way-ANOVA (with repeated measures 
when necessary) for main effects of treatment time and genotype followed by a 
Bonferroni post-hoc analysis. P values of less than 0.05 are considered as statistically 
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